<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="pediatricmusic/PMC4244172/results/search/country/results.xml">
  <result pre="1, L Nuñez-Orozco 1 1CMN 20 de Noviembre, Neurology, Mexico," exact="Mexico" post="Background: According to previous studies, 25% of caregivers of"/>
  <result pre="1, J Hillert 1, C Björkenstam 1 1Karolinska Institutet, Stockholm," exact="Sweden" post="Background: Multiple sclerosis (MS) generally occurs during the most"/>
  <result pre="before diagnosis. P003 Knowledge and attitude towards multiple sclerosis in" exact="Turkey" post="S Canbaz Kabay 1,2, H Ozışık Karaman 2, S"/>
  <result pre="18 Mart University Faculty of Medicine, Department of Neurology, Çanakkale," exact="Turkey" post="Background: Multiple Sclerosis is an inflammatory, autoimmune and neurodegenerative"/>
  <result pre="Austria, 3Klinikum rechts der Isar, Technische Universität München, Neurology, München," exact="Germany" post="Background: Diagnosis and disability associated with multiple sclerosis (MS)"/>
  <result pre="QC, Canada, 2Université Laval, School of Social Work, Quebec, QC," exact="Canada" post="Background: Many studies have presented the physical and psychological"/>
  <result pre="of National and Kapodistrian University, 1st Dept of Psychiatry, Athens," exact="Greece" post="Background: Multiple Sclerosis (MS) is a disease with substantial"/>
  <result pre="Institutet, Neurobiology, Care Science and Society, Division of Nursing, Huddinge," exact="Sweden" post="Background: People with multiple sclerosis (PwMS) use a large"/>
  <result pre="Winnipeg, ON, Canada, 3Manitoba Centre for Health Policy, Winnipeg, ON," exact="Canada" post="Background: People with MS often require increasing amounts of"/>
  <result pre="and Public Health, Rennes, France, 2Rennes University Hospital, Neurology, Rennes," exact="France" post="Background: Introducing oral treatment for multiple sclerosis (MS) relapses"/>
  <result pre="M Grabner 1, A Guo 2 1HealthCore, Inc., Wilmington, DE," exact="United States," post="2Acorda Therapeutics, Inc., Ardsley, NY, United States Background: There"/>
  <result pre="Inc., Wilmington, DE, United States, 2Acorda Therapeutics, Inc., Ardsley, NY," exact="United States" post="Background: There are limited real-world data on treatment patterns"/>
  <result pre="MS II Investigators 1Stanford University School of Medicine, Stanford, CA," exact="United States," post="2Express Scripts, Waldwick, NJ, United States, 3Genzyme, a Sanofi"/>
  <result pre="of Medicine, Stanford, CA, United States, 2Express Scripts, Waldwick, NJ," exact="United States," post="3Genzyme, a Sanofi Company, Cambridge, MA, United States, 4Sanofi"/>
  <result pre="Waldwick, NJ, United States, 3Genzyme, a Sanofi Company, Cambridge, MA," exact="United States," post="4Sanofi R &amp;amp; D, Bridgewater, NJ, United States Background:"/>
  <result pre="Cambridge, MA, United States, 4Sanofi R &amp;amp; D, Bridgewater, NJ," exact="United States" post="Background: Alemtuzumab is approved in over 30 countries for"/>
  <result pre="Yearly disability costs adjusted for inflation were estimated and the" exact="United Kingdom" post="(UK) disability cost estimates were applied as a sensitivity"/>
  <result pre="1, S Cadarette 1, ET Kinter 2 1Evidera, Lexington, MA," exact="United States," post="2Biogen Idec Inc., Cambridge, MA, United States Background: Multiple"/>
  <result pre="1Evidera, Lexington, MA, United States, 2Biogen Idec Inc., Cambridge, MA," exact="United States" post="Background: Multiple Sclerosis (MS) is a debilitating disease associated"/>
  <result pre="conducted in Europe (41), North America (5), South America (6)," exact="Australia" post="(1), and Asia (3) were included. The majority of"/>
  <result pre="I and II Investigators 1Genzyme, a Sanofi Company, Cambridge, MA," exact="United States," post="2University of Alabama at Birmingham, Department of Biostatistics, Birmingham,"/>
  <result pre="2University of Alabama at Birmingham, Department of Biostatistics, Birmingham, AL," exact="United States," post="3University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom, 4Genzyme,"/>
  <result pre="Birmingham, AL, United States, 3University of Cambridge, Addenbrooke’s Hospital, Cambridge," exact="United Kingdom," post="4Genzyme, a Sanofi Company, Stockholm, Sweden Background: Alemtuzumab is"/>
  <result pre="Addenbrooke’s Hospital, Cambridge, United Kingdom, 4Genzyme, a Sanofi Company, Stockholm," exact="Sweden" post="Background: Alemtuzumab is approved in over 30 countries for"/>
  <result pre="compared with high-dose, high-frequency interferon in active RRMS patients in" exact="Sweden" post="from a payer perspective. P014 Sources of income for"/>
  <result pre="for individuals with multiple sclerosis: a nationwide population-based study in" exact="Sweden" post="M Wiberg 1, E Friberg 1, K Alexanderson 1,"/>
  <result pre="1, J Hillert 1, P Tinghög 1 1Karolinska Institutet, Stockholm," exact="Sweden" post="Background: Multiple sclerosis (MS) is associated with labour market"/>
  <result pre="social benefits compared to others. Methods: From all residents in" exact="Sweden" post="aged 21-64 years in 2010 (n=5,318,764), those with a"/>
  <result pre="1Icahn School of Medicine at Mount Sinai, New York, NY," exact="United States," post="2Houston Methodist Hospital, Houston, TX, United States, 3Mount Sinai"/>
  <result pre="New York, NY, United States, 2Houston Methodist Hospital, Houston, TX," exact="United States," post="3Mount Sinai Hospital, New York, NY, United States, 4Mount"/>
  <result pre="Houston, TX, United States, 3Mount Sinai Hospital, New York, NY," exact="United States," post="4Mount Sinai St. Luke’s, New York, NY, United States,"/>
  <result pre="NY, United States, 4Mount Sinai St. Luke’s, New York, NY," exact="United States," post="5Saint Louis University, Saint Louis, MO, United States, 6Detroit"/>
  <result pre="York, NY, United States, 5Saint Louis University, Saint Louis, MO," exact="United States," post="6Detroit Medical Center, Detroit, MI, United States, 7Michigan State"/>
  <result pre="Saint Louis, MO, United States, 6Detroit Medical Center, Detroit, MI," exact="United States," post="7Michigan State University, East Lansing, MI, United States Background:"/>
  <result pre="Detroit, MI, United States, 7Michigan State University, East Lansing, MI," exact="United States" post="Background: Multiple Sclerosis (MS) is a neurological disorder without"/>
  <result pre="1, HL Weiner 1, R Bakshi 1 1Harvard/BWH, Boston, MA," exact="United States," post="2Novartis Pharmaceuticals, East Hanover, NJ, United States, 3Analysis Group,"/>
  <result pre="1Harvard/BWH, Boston, MA, United States, 2Novartis Pharmaceuticals, East Hanover, NJ," exact="United States," post="3Analysis Group, Boston, MA, United States Background: The compromised"/>
  <result pre="Pharmaceuticals, East Hanover, NJ, United States, 3Analysis Group, Boston, MA," exact="United States" post="Background: The compromised ability to perform occupational functions is"/>
  <result pre="and cost in multiple sclerosis - a cross-sectional study from" exact="Slovakia" post="V Donath 1, M Ondrusova 2 1F.D.Roosevelt Teaching Hospital,"/>
  <result pre="2 1F.D.Roosevelt Teaching Hospital, Neurology, Banska Bystrica, Slovakia, 2Pharm-In, Bratislava," exact="Slovakia" post="Background: Currently, MS treatment focuses on preventing relapses and"/>
  <result pre="the direct costs associated with health-care management of MS in" exact="Slovakia" post="and to provide a basis for cost-effectiveness evaluations. Methods:"/>
  <result pre="1, S Cadarette 1, ET Kinter 2 1Evidera, Lexington, MA," exact="United States," post="2Biogen Idec Inc., Cambridge, MA, United States Background: Multiple"/>
  <result pre="1Evidera, Lexington, MA, United States, 2Biogen Idec Inc., Cambridge, MA," exact="United States" post="Background: Multiple sclerosis (MS) is a debilitating disease associated"/>
  <result pre="utility longer. P019 Cost of MS - patients’ burden in" exact="Norway" post="BO Svendsen 1, K-M Myhr 2, NG Torkildsen 1,"/>
  <result pre="Bergen, Norway, 2University of Bergen, Department of Clinical Medicine, Bergen," exact="Norway" post="Background: Multiple sclerosis (MS) often implies a high burden"/>
  <result pre="1Brigham and Women’s Hospital, Harvard Medical School, Psychiatry, Boston, MA," exact="United States" post="Background: The National Multiple Sclerosis Society’s (NMSS) Sonya Slifka"/>
  <result pre="of almost 2,200 individuals with multiple sclerosis (MS) in the" exact="United States" post="(US). A second cohort of nearly 2,500 patients was"/>
  <result pre="Pacheco 1 1Novartis Farma - Produtos Farmacêuticos S.A., Porto Salvo," exact="Portugal" post="Background: Treatment of Multiple Sclerosis (MS) is associated with"/>
  <result pre="(MS) is associated with significant clinical and economic burden. In" exact="Portugal" post="there are about 2,694 patients treated with interferon beta"/>
  <result pre="Dublin, Ireland, 2National Centre for Pharmacoeconomics, St James’ Hospital, Dublin," exact="Ireland" post="Background: Multiple sclerosis (MS) commonly affects young adults and"/>
  <result pre="J Cooper 3 1Jordan Research &amp;amp; Education Institute, Berkeley, CA," exact="United States," post="2Kaiser Permanente, Oakland, CA, United States, 3Alta Bates Summit"/>
  <result pre="Education Institute, Berkeley, CA, United States, 2Kaiser Permanente, Oakland, CA," exact="United States," post="3Alta Bates Summit Medical Center, Berkeley, CA, United States,"/>
  <result pre="CA, United States, 3Alta Bates Summit Medical Center, Berkeley, CA," exact="United States," post="4Central Texas Neurology Consultants, Round Rock, TX, United States,"/>
  <result pre="CA, United States, 4Central Texas Neurology Consultants, Round Rock, TX," exact="United States," post="5UT Southwestern Medical Center at Dallas, Dallas, TX, United"/>
  <result pre="United States, 5UT Southwestern Medical Center at Dallas, Dallas, TX," exact="United States" post="Background: The Functional Index for Living with Multiple Sclerosis"/>
  <result pre="Siena, Department of Physiopathology, Experimental Medicine and Public Health, Siena," exact="Italy" post="Background: The effects of multiple sclerosis (MS) are wide-ranging,"/>
  <result pre="Bangkok, Thailand, 4Sriphat Medical Center, Chiang Mai University, Chiang Mai," exact="Thailand" post="Background: Increasing awareness of Thai patients with Idiopathic Inflammatory"/>
  <result pre="N Thomas 3 1Truven Health Analytics, Life Sciences, Cambridge, MA," exact="United States," post="2Independent Consultant, Bend, OR, United States, 3Genentech, San Francisco,"/>
  <result pre="Life Sciences, Cambridge, MA, United States, 2Independent Consultant, Bend, OR," exact="United States," post="3Genentech, San Francisco, CA, United States Background: Among patients"/>
  <result pre="2Independent Consultant, Bend, OR, United States, 3Genentech, San Francisco, CA," exact="United States" post="Background: Among patients with multiple sclerosis (MS), few studies"/>
  <result pre="Doshi 2 1University of Pennsylvania, Department of Neurology, Philadelphia, PA," exact="United States," post="2University of Pennsylvania, Department of Medicine, Philadelphia, PA, United"/>
  <result pre="United States, 2University of Pennsylvania, Department of Medicine, Philadelphia, PA," exact="United States" post="Background: Treatment for Multiple Sclerosis (MS) and related symptoms"/>
  <result pre="(DMT) and the impact of symptomatic treatment nationally in the" exact="United States" post="(US). Objectives: To estimate the prevalence of DMT and"/>
  <result pre="1Novartis Pharma GmbH, Nuremberg, Germany, 2Universitätsklinikum Karl Gustav Carus, Dresden," exact="Germany" post="Background: The PEARL study ( Prosp Ective ph Armacoeconomic"/>
  <result pre="Duh 1, R Iyer 3 1Analysis Group Inc, Boston, MA," exact="United States," post="2Biogen Idec Inc., Weston, MA, United States, 3Biogen Idec"/>
  <result pre="Inc, Boston, MA, United States, 2Biogen Idec Inc., Weston, MA," exact="United States," post="3Biogen Idec Inc., Cambridge, MA, United States Background: Adherence"/>
  <result pre="Inc., Weston, MA, United States, 3Biogen Idec Inc., Cambridge, MA," exact="United States" post="Background: Adherence to disease modifying therapy (DMT) is suboptimal"/>
  <result pre="France, 7University Clinic Carl Gustav Carus, Department of Neurology, Dresden," exact="Germany" post="Background: The therapeutic arsenal for patients with relapsing-remitting multiple"/>
  <result pre="Business Research Unit, Lisboa, Portugal, 2Hospital de São João, Porto," exact="Portugal" post="Background: In recent years there has been a growing"/>
  <result pre="activity among patients with relapsing remitting multiple sclerosis in the" exact="United States" post="and Europe P O’Meara 1, S Narayanan 2, J"/>
  <result pre="Chan 3, S Gabriele 3 1Ipsos Healthcare, New York, NY," exact="United States," post="2Ipsos Healthcare, Columbia, MD, United States, 3Ipsos Healthcare, London,"/>
  <result pre="Healthcare, New York, NY, United States, 2Ipsos Healthcare, Columbia, MD," exact="United States," post="3Ipsos Healthcare, London, United Kingdom Background: Progression of symptoms"/>
  <result pre="States, 2Ipsos Healthcare, Columbia, MD, United States, 3Ipsos Healthcare, London," exact="United Kingdom" post="Background: Progression of symptoms among Relapsing Remitting Multiple Sclerosis"/>
  <result pre="disease activity/progression among RRMS pts in Europe (EU) and the" exact="United States" post="(US) is lacking. Objectives: To assess the patterns of"/>
  <result pre="Basel, Switzerland, 3Novartis Pharma AG, Basel, Switzerland, 4Microsoft Research, Cambridge," exact="United Kingdom," post="5Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States Background:"/>
  <result pre="Research, Cambridge, United Kingdom, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ," exact="United States" post="Background: Measurement instruments used in the neurological examination, including"/>
  <result pre="Basel, Switzerland, 4Claudiabasel GmbH, Basel, Switzerland, 5Novartis Pharma AG, Basel," exact="Switzerland" post="Background: The Expanded Disability Status Scale (EDSS) is the"/>
  <result pre="2VU University Medical Center, Neurology, Amsterdam, Netherlands, 3Microsoft Research, Cambridge," exact="United Kingdom," post="4Novartis Pharma AG, Basel, Switzerland, 5Novartis Pharmaceuticals Corporation, East"/>
  <result pre="Pharma AG, Basel, Switzerland, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ," exact="United States" post="Background: The Expanded Disability Status Scale (EDSS) is the"/>
  <result pre="des Sciences de l’Education, Mons, Belgium, 6National MS Center, Melsbroek," exact="Belgium" post="Background: Hand function is commonly impaired in Multiple Sclerosis"/>
  <result pre="Cutter 2 1University of Alabama at Birmingham, Epidemiology, Birmingham, AL," exact="United States," post="2University of Alabama at Birmingham, Biostatistics, Birmingham, AL, United"/>
  <result pre="United States, 2University of Alabama at Birmingham, Biostatistics, Birmingham, AL," exact="United States," post="3New York University, Neurology, New York, NY, United States"/>
  <result pre="AL, United States, 3New York University, Neurology, New York, NY," exact="United States" post="Background: We recently used item response theory (IRT) methodology"/>
  <result pre="Clinic, Mellen Center for MS Treatment and Research, Cleveland, OH," exact="United States," post="2Cleveland Clinic, Biomedical Engineering, Cleveland, OH, United States, 3Cleveland"/>
  <result pre="Cleveland, OH, United States, 2Cleveland Clinic, Biomedical Engineering, Cleveland, OH," exact="United States," post="3Cleveland Clinic, Center for Brain Health, Cleveland, OH, United"/>
  <result pre="United States, 3Cleveland Clinic, Center for Brain Health, Cleveland, OH," exact="United States," post="4Cleveland Clinic, Quantitative Health Sciences, Cleveland, OH, United States"/>
  <result pre="OH, United States, 4Cleveland Clinic, Quantitative Health Sciences, Cleveland, OH," exact="United States" post="Background: Impairment of upper extremity (UE) function is a"/>
  <result pre="QC, Canada, 4Cleveland Clinic, Department of Biomedical Engineering, Cleveland, OH," exact="United States," post="5Genzyme, a Sanofi Company, Cambridge, MA, United States Background:"/>
  <result pre="Cleveland, OH, United States, 5Genzyme, a Sanofi Company, Cambridge, MA," exact="United States" post="Background: In the CARE-MS I (NCT00530348) trial in treatment-naive"/>
  <result pre="1University of Texas Health Science Center at Houston, Houston, TX," exact="United States," post="2Genzyme, a Sanofi Company, Chilly-Mazarin, France, 3Sanofi, Bridgewater, NJ,"/>
  <result pre="States, 2Genzyme, a Sanofi Company, Chilly-Mazarin, France, 3Sanofi, Bridgewater, NJ," exact="United States," post="4Icahn School of Medicine at Mount Sinai, New York,"/>
  <result pre="4Icahn School of Medicine at Mount Sinai, New York, NY," exact="United States" post="Background: Teriflunomide is a once-daily oral immunomodulator approved for"/>
  <result pre="1McGill University, Montreal, QC, Canada, 2University of Colorado, Aurora, CO," exact="United States," post="3Teva Pharmaceutical Industries, Netanya, Israel, 4Teva Pharmaceutical Industries, Frazer,"/>
  <result pre="3Teva Pharmaceutical Industries, Netanya, Israel, 4Teva Pharmaceutical Industries, Frazer, PA," exact="United States," post="5Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany, 6NeuroRx Research, Montreal, QC,"/>
  <result pre="States, 5Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany, 6NeuroRx Research, Montreal, QC," exact="Canada" post="Background: Laquinimod (LAQ) is an oral immunomodulator under development"/>
  <result pre="Düsseldorf, Germany, 2Alleghany General Hospital, Department of Neurology, Pittsburgh, PA," exact="United States," post="3Drexel University College of Medicine, Department of Neurology, Pittsburgh,"/>
  <result pre="3Drexel University College of Medicine, Department of Neurology, Pittsburgh, PA," exact="United States," post="4Johns Hopkins School of Medicine, Department of Neurology, Baltimore,"/>
  <result pre="4Johns Hopkins School of Medicine, Department of Neurology, Baltimore, MD," exact="United States," post="5Biogen Idec Inc., Cambridge, MA, United States Background: At"/>
  <result pre="Neurology, Baltimore, MD, United States, 5Biogen Idec Inc., Cambridge, MA," exact="United States" post="Background: At Year 1 of the Phase 3 ADVANCE"/>
  <result pre="Center and Department of Biomedical Engineering, Cleveland Clinic, Cleveland, OH," exact="United States," post="4University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom, 5University"/>
  <result pre="Cleveland, OH, United States, 4University of Cambridge, Addenbrooke’s Hospital, Cambridge," exact="United Kingdom," post="5University of Texas Medical Branch, Round Rock, TX, United"/>
  <result pre="United Kingdom, 5University of Texas Medical Branch, Round Rock, TX," exact="United States," post="6Department of Neurology, First School of Medicine, Charles University,"/>
  <result pre="6Department of Neurology, First School of Medicine, Charles University, Prague," exact="Czech Republic," post="7Medical University of Łódź, Department of Neurology, Łódź, Poland,"/>
  <result pre="of Neurology, Łódź, Poland, 8Genzyme, a Sanofi Company, Cambridge, MA," exact="United States," post="9Department of Clinical Neurosciences, University of Cambridge, Cambridge, United"/>
  <result pre="United States, 9Department of Clinical Neurosciences, University of Cambridge, Cambridge," exact="United Kingdom" post="Background: Alemtuzumab is approved in over 30 countries for"/>
  <result pre="University Hospital, Dijon, France, 2Genzyme, a Sanofi Company, Cambridge, MA," exact="United States," post="3PROMETRIKA, LLC, Cambridge, MA, United States, 4MS Center for"/>
  <result pre="Sanofi Company, Cambridge, MA, United States, 3PROMETRIKA, LLC, Cambridge, MA," exact="United States," post="4MS Center for Innovations in Care, St. Louis, MO,"/>
  <result pre="States, 4MS Center for Innovations in Care, St. Louis, MO," exact="United States" post="Background: Alemtuzumab is approved in over 30 countries for"/>
  <result pre="1 1University of Genoa, Health Sciences, Section of Biostatistics, Genoa," exact="Italy" post="Background: In recent years post-hoc analyses of clinical trials"/>
  <result pre="Ottawa Hospital Research Institute, Ottawa, ON, Canada, 2Sanofi, Bridgewater, NJ," exact="United States," post="3Genzyme, a Sanofi Company, Chilly-Mazarin, France, 4University Hospital Basel,"/>
  <result pre="3Genzyme, a Sanofi Company, Chilly-Mazarin, France, 4University Hospital Basel, Basel," exact="Switzerland" post="Background: Teriflunomide is a once-daily oral immunomodulator approved for"/>
  <result pre="Health Science Center at Houston, Department of Neurology, Houston, TX," exact="United States," post="3Novartis Pharma AG, Basel, Switzerland, 4Novartis Pharmaceuticals Corporation, East"/>
  <result pre="Pharma AG, Basel, Switzerland, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ," exact="United States," post="5VU Medical Centre, Image Analysis Centre, Amsterdam, Netherlands Background:"/>
  <result pre="NJ, United States, 5VU Medical Centre, Image Analysis Centre, Amsterdam," exact="Netherlands" post="Background: Analysis of brain volume (BV) in patients with"/>
  <result pre="Copenhagen, Denmark, 2GlaxoSmithKline, Clinical Statistics, Neurosciences, Research Triangle Park, NC," exact="United States," post="3GlaxoSmithKline, Clinical Pharmacology, Stockley Park West, United Kingdom, 4GlaxoSmithKline,"/>
  <result pre="Park, NC, United States, 3GlaxoSmithKline, Clinical Pharmacology, Stockley Park West," exact="United Kingdom," post="4GlaxoSmithKline, Clinical Statistics, Neurosciences, Stockley Park West, United Kingdom,"/>
  <result pre="West, United Kingdom, 4GlaxoSmithKline, Clinical Statistics, Neurosciences, Stockley Park West," exact="United Kingdom," post="5GlaxoSmithKline, Stiefel Global Clinical Dev US, Research Triangle Park,"/>
  <result pre="5GlaxoSmithKline, Stiefel Global Clinical Dev US, Research Triangle Park, NC," exact="United States," post="6GlaxoSmithKline, RD Projects Clinical Platforms &amp;amp; Sciences, Research Triangle"/>
  <result pre="RD Projects Clinical Platforms &amp;amp; Sciences, Research Triangle Park, NC," exact="United States," post="7GlaxoSmithKline, Neurosciences Therapy Area Unit, Research Triangle Park, NC,"/>
  <result pre="States, 7GlaxoSmithKline, Neurosciences Therapy Area Unit, Research Triangle Park, NC," exact="United States," post="8McGill University and McGill University Health Center, Montreal Neurological"/>
  <result pre="University Health Center, Montreal Neurological Institute and Hospital, Montreal, QC," exact="Canada" post="Background: Studies have demonstrated the benefits of anti-CD20 monoclonal"/>
  <result pre="3University Hospital Zürich, Department of Neuroimmunology and MS Research, Zürich," exact="Switzerland" post="Background: Orally available drugs exhibiting a safe and favourable"/>
  <result pre="E Legangneux 1, E Wallström 1 1Novartis Pharma AG, Basel," exact="Switzerland" post="Background: Siponimod (BAF312) is an orally administered sphingosine 1-phosphate"/>
  <result pre="Hospital, Basel, Switzerland, 4First School of Medicine, Charles University, Prague," exact="Czech Republic," post="5Medical University of Lodz, Lodz, Poland, 6Moscow Multiple Sclerosis"/>
  <result pre="University of Lodz, Lodz, Poland, 6Moscow Multiple Sclerosis Center, Moscow," exact="Russian Federation," post="7Carolinas Medical Center, Charlotte, NC, United States, 8University of"/>
  <result pre="Sclerosis Center, Moscow, Russian Federation, 7Carolinas Medical Center, Charlotte, NC," exact="United States," post="8University of Münster, Münster, Germany, 9University of Utah Medical"/>
  <result pre="Germany, 9University of Utah Medical School, Salt Lake City, UT," exact="United States," post="10Abbvie Biotherapeutics Inc, Redwood City, CA, United States, 11Biogen"/>
  <result pre="City, UT, United States, 10Abbvie Biotherapeutics Inc, Redwood City, CA," exact="United States," post="11Biogen Idec, Cambridge, MA, United States Background: The humanized"/>
  <result pre="Inc, Redwood City, CA, United States, 11Biogen Idec, Cambridge, MA," exact="United States" post="Background: The humanized IgG1 monoclonal antibody daclizumab high-yield process"/>
  <result pre="Zambrano 2 1Department of Neurology, Georgetown University Hospital, Washington, DC," exact="United States," post="2Biogen Idec, Inc., Cambridge, MA, United States, 3PharmStats, Ltd.,"/>
  <result pre="Hospital, Washington, DC, United States, 2Biogen Idec, Inc., Cambridge, MA," exact="United States," post="3PharmStats, Ltd., Escondido, CA, United States Background: Delayed-release dimethyl"/>
  <result pre="Idec, Inc., Cambridge, MA, United States, 3PharmStats, Ltd., Escondido, CA," exact="United States" post="Background: Delayed-release dimethyl fumarate (DMF) demonstrated efficacy and safety"/>
  <result pre="O Khan 8,9 1University of Alabama at Birmingham, Birmingham, AL," exact="United States," post="2University of Texas, Health Science Center at Houston, Houston,"/>
  <result pre="2University of Texas, Health Science Center at Houston, Houston, TX," exact="United States," post="3San Raffaele Scientific Institute and Vita-Salute San Raffaele University,"/>
  <result pre="Pharmaceutical Industries, Petach Tiqva, Israel, 5Teva Pharmaceutical Industries, Frazer, PA," exact="United States," post="6Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany, 7Teva Pharmaceutical Industries, Netanya,"/>
  <result pre="Sclerosis Center, Wayne State University School of Medicine, Detroit, MI," exact="United States," post="9Sastry Foundation Advanced Imaging Laboratory, Wayne State University School"/>
  <result pre="Imaging Laboratory, Wayne State University School of Medicine, Detroit, MI," exact="United States" post="Background: The GALA study in RRMS showed the safety"/>
  <result pre="Gorfine 2, PS Sørensen 4 1University of Colorado, Aurora, CO," exact="United States," post="2Teva Pharmaceutical Industries, Netanya, Israel, 3Teva Pharmaceutical Industries, Petach"/>
  <result pre="Pharmaceutical Industries, Petach Tiqva, Israel, 4Copenhagen University Hospital, Rigshospitalet, Copenhagen," exact="Denmark" post="Background: The BRAVO study assessed the efficacy, safety, and"/>
  <result pre="V Yadav 1,2, G Maracci 1,2, E Kim 1,2, R" exact="Spain" post="1,2, M Cameron 1,2, S Overs 3, A Lewis"/>
  <result pre="Bourdette 1,2 1Oregon Health &amp;amp; Science University, Neurology, Portland, OR," exact="United States," post="2Portland Veterans’ Affairs Medical Center, Neurology, Portland, OR, United"/>
  <result pre="United States, 2Portland Veterans’ Affairs Medical Center, Neurology, Portland, OR," exact="United States," post="3Novant Medical Group, Charlotte, OR, United States, 4McDougall Research"/>
  <result pre="Neurology, Portland, OR, United States, 3Novant Medical Group, Charlotte, OR," exact="United States," post="4McDougall Research and Education Foundation, Santa Rosa, CA, United"/>
  <result pre="United States, 4McDougall Research and Education Foundation, Santa Rosa, CA," exact="United States," post="5Louisiana State University, Neurology, New Orleans, LA, United States,"/>
  <result pre="CA, United States, 5Louisiana State University, Neurology, New Orleans, LA," exact="United States," post="6Lsu, Neurology, Neurology, LA, United States Background: Despite use"/>
  <result pre="Neurology, New Orleans, LA, United States, 6Lsu, Neurology, Neurology, LA," exact="United States" post="Background: Despite use of disease modifying therapies, poor quality"/>
  <result pre="France, 8CHU de Bordeaux, Service de Neurologie, Hôpital Pellegrin, Bordeaux," exact="France" post="Background: There is no validated therapeutic strategy available to"/>
  <result pre="Barts and the London School of Medicine and Dentistry, London," exact="United Kingdom," post="2St. Josef Hospital, Ruhr University, Bochum, Germany, 3University Hospital,"/>
  <result pre="Neurological Institute, Montreal, QC, Canada, 5Biogen Idec Inc., Cambridge, MA," exact="United States" post="Background: Delayed-release dimethyl fumarate (DMF) demonstrated efficacy on clinical"/>
  <result pre="1University of Texas Health Science Center at Houston, Houston, TX," exact="United States," post="2Sanofi, Bridgewater, NJ, United States, 3Genzyme, a Sanofi Company,"/>
  <result pre="Center at Houston, Houston, TX, United States, 2Sanofi, Bridgewater, NJ," exact="United States," post="3Genzyme, a Sanofi Company, Chilly-Mazarin, France, 4University Hospital Basel,"/>
  <result pre="3Genzyme, a Sanofi Company, Chilly-Mazarin, France, 4University Hospital Basel, Basel," exact="Switzerland" post="Background: Teriflunomide is a once-daily oral immunomodulator approved for"/>
  <result pre="for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH," exact="United States," post="4St. Josef Hospital, Ruhr University, Bochum, Germany, 5Charles University,"/>
  <result pre="5Charles University, Department of Neurology, First Faculty of Medicine, Prague," exact="Czech Republic," post="6University Hospital, Basel Neurology, Basel, Switzerland, 7University College London"/>
  <result pre="Neurology, Queen Square Multiple Sclerosis Centre, NMR Research Unit, London," exact="United Kingdom," post="8Biogen Idec Inc., Cambridge, MA, United States Background: Delayed-release"/>
  <result pre="Research Unit, London, United Kingdom, 8Biogen Idec Inc., Cambridge, MA," exact="United States" post="Background: Delayed-release dimethyl fumarate (DMF) demonstrated efficacy and safety"/>
  <result pre="4Icahn School of Medicine at Mount Sinai, New York, NY," exact="United States," post="5Karolinska Institute, Stockholm, Sweden, 6University of Texas Health Science"/>
  <result pre="6University of Texas Health Science Center at Houston, Houston, TX," exact="United States," post="7Genzyme, a Sanofi Company, Chilly-Mazarin, France, 8Sanofi, Bridgewater, NJ,"/>
  <result pre="States, 7Genzyme, a Sanofi Company, Chilly-Mazarin, France, 8Sanofi, Bridgewater, NJ," exact="United States," post="9University of Toronto, Toronto, ON, Canada Background: Teriflunomide is"/>
  <result pre="8Sanofi, Bridgewater, NJ, United States, 9University of Toronto, Toronto, ON," exact="Canada" post="Background: Teriflunomide is a once-daily oral immunomodulator approved for"/>
  <result pre="San Raffaele University, Milan, Italy, 2University of Colorado, Aurora, CO," exact="United States," post="3Clinical Research and Biomedicine, University Hospital Basel, Basel, Switzerland,"/>
  <result pre="5Teva Pharmaceutical Industries, Netanya, Israel, 6Teva Pharmaceutical Industries, Frazer, PA," exact="United States," post="7Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany Background: Once-daily oral laquinimod"/>
  <result pre="Pharmaceutical Industries, Frazer, PA, United States, 7Heinrich-Heine Universität Düsseldorf, Düsseldorf," exact="Germany" post="Background: Once-daily oral laquinimod 0.6mg has demonstrated efficacy in"/>
  <result pre="Gorfine 7, V Knappertz 6,8 1University of Colorado, Aurora, CO," exact="United States," post="2San Raffaele Scientific Institute and Vita-Salute San Raffaele University,"/>
  <result pre="d’Hebron, Barcelona, Spain, 5University of Alabama at Birmingham, Birmingham, AL," exact="United States," post="6Teva Pharmaceutical Industries, Frazer, PA, United States, 7Teva Pharmaceutical"/>
  <result pre="Birmingham, Birmingham, AL, United States, 6Teva Pharmaceutical Industries, Frazer, PA," exact="United States," post="7Teva Pharmaceutical Industries, Netanya, Israel, 8Heinrich-Heine Universität Düsseldorf, Düsseldorf,"/>
  <result pre="States, 7Teva Pharmaceutical Industries, Netanya, Israel, 8Heinrich-Heine Universität Düsseldorf, Düsseldorf," exact="Germany" post="Background: In patients (pts) with relapsing remitting MS (RRMS)"/>
  <result pre="1028 et CNRS UMR 5292, Equipe Neuro-Oncologie et Neuro-Inflammation, Lyon," exact="France" post="Background: Women are affected by multiple sclerosis (MS) mainly"/>
  <result pre="Barts and the London School of Medicine and Dentistry, London," exact="United Kingdom," post="3Baylor Institute for Immunology Research, Multiple Sclerosis Program, Dallas,"/>
  <result pre="3Baylor Institute for Immunology Research, Multiple Sclerosis Program, Dallas, TX," exact="United States," post="4Cleveland Clinic, Mellen Center for Multiple Sclerosis Treatment and"/>
  <result pre="Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, OH," exact="United States," post="5Biogen Idec Inc., Cambridge, MA, United States Background: Delayed-release"/>
  <result pre="Research, Cleveland, OH, United States, 5Biogen Idec Inc., Cambridge, MA," exact="United States" post="Background: Delayed-release dimethyl fumarate (DMF) demonstrated efficacy and safety"/>
  <result pre="reported, as this represents the approved maintenance dosage in the" exact="United States" post="and European Union. The GA arm was excluded from"/>
  <result pre="Barts and the London School of Medicine and Dentistry, London," exact="United Kingdom," post="3Cleveland Clinic, Mellen Center for Multiple Sclerosis Treatment and"/>
  <result pre="Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, OH," exact="United States," post="4St. Josef Hospital, Ruhr University, Bochum, Germany, 5Baylor Institute"/>
  <result pre="5Baylor Institute for Immunology Research, Multiple Sclerosis Program, Dallas, TX," exact="United States," post="6Biogen Idec Inc., Cambridge, MA, United States Background: Delayed-release"/>
  <result pre="Program, Dallas, TX, United States, 6Biogen Idec Inc., Cambridge, MA," exact="United States" post="Background: Delayed-release dimethyl fumarate (DMF) improved relapse outcomes and"/>
  <result pre="2Baylor Institute for Immunology Research, Multiple Sclerosis Program, Dallas, TX," exact="United States," post="3Cleveland Clinic, Mellen Center for Multiple Sclerosis Treatment and"/>
  <result pre="Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, OH," exact="United States," post="4Medical University of Lodz, Lodz, Poland, 5Biogen Idec Inc.,"/>
  <result pre="University of Lodz, Lodz, Poland, 5Biogen Idec Inc., Cambridge, MA," exact="United States," post="6St. Josef Hospital, Ruhr University, Bochum, Germany Background: The"/>
  <result pre="Cambridge, MA, United States, 6St. Josef Hospital, Ruhr University, Bochum," exact="Germany" post="Background: The efficacy and safety of oral delayed-release dimethyl"/>
  <result pre="QC, Canada, 3Johns Hopkins University, Department of Neurology, Baltimore, MD," exact="United States," post="4Heinrich-Heine University, Department of Neurology, Düsseldorf, Germany, 5Biogen Idec"/>
  <result pre="Department of Neurology, Düsseldorf, Germany, 5Biogen Idec Inc., Cambridge, MA," exact="United States" post="Background: Subcutaneous (SC) peginterferon beta-1a (PEG-IFN) provided improvements in"/>
  <result pre="Gorfine 6, V Knappertz 5,7 1University of Colorado, Aurora, CO," exact="United States," post="2San Raffaele Scientific Institute and Vita-Salute San Raffaele University,"/>
  <result pre="University, Milan, Italy, 3University of Alabama at Birmingham, Birmingham, AL," exact="United States," post="4Hospital Universitari de la Vall d’Hebron, Barcelona, Spain, 5Teva"/>
  <result pre="la Vall d’Hebron, Barcelona, Spain, 5Teva Pharmaceutical Industries, Frazer, PA," exact="United States," post="6Teva Pharmaceutical Industries, Netanya, Israel, 7Heinrich-Heine Universität Düsseldorf, Düsseldorf,"/>
  <result pre="States, 6Teva Pharmaceutical Industries, Netanya, Israel, 7Heinrich-Heine Universität Düsseldorf, Düsseldorf," exact="Germany" post="Background: In pooled data from the Phase III ALLEGRO"/>
  <result pre="1University of Genoa, Genoa, Italy, 2University of Colorado, Aurora, CO," exact="United States," post="3San Raffaele Scientific Institute and Vita-Salute San Raffaele University,"/>
  <result pre="4Teva Pharmaceutical Industries, Netanya, Israel, 5Teva Pharmaceutical Industries, Frazer, PA," exact="United States," post="6Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany Background: Patients (pts) with"/>
  <result pre="Pharmaceutical Industries, Frazer, PA, United States, 6Heinrich-Heine Universität Düsseldorf, Düsseldorf," exact="Germany" post="Background: Patients (pts) with RRMS treated with oral laquinimod"/>
  <result pre="San Raffaele University, Milan, Italy, 2University of Colorado, Aurora, CO," exact="United States," post="3Clinical Research and Biomedicine, University Hospital Basel, Basel, Switzerland,"/>
  <result pre="5Teva Pharmaceutical Industries, Netanya, Israel, 6Teva Pharmaceutical Industries, Frazer, PA," exact="United States," post="7Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany Background: Oral laquinimod 0.6mg"/>
  <result pre="Pharmaceutical Industries, Frazer, PA, United States, 7Heinrich-Heine Universität Düsseldorf, Düsseldorf," exact="Germany" post="Background: Oral laquinimod 0.6mg once-daily (QD) demonstrated consistent reductions"/>
  <result pre="Gorfine 4, V Knappertz 5,6 1University of Colorado, Aurora, CO," exact="United States," post="2San Raffaele Scientific Institute and Vita-Salute San Raffaele University,"/>
  <result pre="4Teva Pharmaceutical Industries, Netanya, Israel, 5Teva Pharmaceutical Industries, Frazer, PA," exact="United States," post="6Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany Background: The precise mechanism"/>
  <result pre="Pharmaceutical Industries, Frazer, PA, United States, 6Heinrich-Heine Universität Düsseldorf, Düsseldorf," exact="Germany" post="Background: The precise mechanism of action of laquinimod and"/>
  <result pre="4University Hospital Hvidovre, Danish Research Centre for Magnetic Resonance, Copenhagen," exact="Denmark" post="Background: Erythropoietin, (EPO) a haematopoietic growth factor may be"/>
  <result pre="S Belachew 2 1Mellen Center, Cleveland Clinic Foundation, Cleveland, OH," exact="United States," post="2Biogen Idec, Cambridge, MA, United States Background: MS patients"/>
  <result pre="Clinic Foundation, Cleveland, OH, United States, 2Biogen Idec, Cambridge, MA," exact="United States" post="Background: MS patients can have fluctuating and variable disease"/>
  <result pre="Phillips 1, B Sperling 1 1Biogen Idec Inc., Cambridge, MA," exact="United States," post="2Evidera, Lexington, MA, United States, 3Evidera, Montreal, QC, Canada"/>
  <result pre="1Biogen Idec Inc., Cambridge, MA, United States, 2Evidera, Lexington, MA," exact="United States," post="3Evidera, Montreal, QC, Canada Background: ADVANCE, a Phase 3,"/>
  <result pre="United States, 2Evidera, Lexington, MA, United States, 3Evidera, Montreal, QC," exact="Canada" post="Background: ADVANCE, a Phase 3, randomized, double-blind study, showed"/>
  <result pre="Amsterdam, Netherlands, 2Cleveland Clinic, Department of Biomedical Engineering, Cleveland, OH," exact="United States," post="3Genzyme, a Sanofi Company, Cambridge, MA, United States, 4NeuroRx"/>
  <result pre="Cleveland, OH, United States, 3Genzyme, a Sanofi Company, Cambridge, MA," exact="United States," post="4NeuroRx Research, Montréal, QC, Canada, 5Department of Neurology and"/>
  <result pre="Neurology and Neurosurgery, Montréal Neurological Institute, McGill University, Montreal, QC," exact="Canada" post="Background: In the phase 3 CARE-MS II trial (NCT00548405)"/>
  <result pre="technologies BV, Leiden, Netherlands, 2Centre for Human Drug Research, Leiden," exact="Netherlands" post="Background: Intravenous high-dose methylprednisolone (MP, 500- 1000 mg daily"/>
  <result pre="for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH," exact="United States," post="2St. Josef Hospital, Ruhr University, Bochum, Germany, 3Multiple Sclerosis"/>
  <result pre="3Multiple Sclerosis Program, Baylor Institute for Immunology Research, Dallas, TX," exact="United States," post="4Medical University of Lodz, Lodz, Poland, 5Biogen Idec, Inc.,"/>
  <result pre="University of Lodz, Lodz, Poland, 5Biogen Idec, Inc., Cambridge, MA," exact="United States" post="Background: Delayed-release dimethyl fumarate (DMF) demonstrated efficacy and safety"/>
  <result pre="Cavalier 6 1Stony Brook University Medical Center, Stony Brook, NY," exact="United States," post="2Multiple Sclerosis Center of Northeastern New York, Latham, NY,"/>
  <result pre="States, 2Multiple Sclerosis Center of Northeastern New York, Latham, NY," exact="United States," post="3Regional MS Center, Center for Neurological Disorders, Milwaukee, WI,"/>
  <result pre="States, 3Regional MS Center, Center for Neurological Disorders, Milwaukee, WI," exact="United States," post="4North Central Neurology Associates, Cullman, AL, United States, 5Lincoln,"/>
  <result pre="Milwaukee, WI, United States, 4North Central Neurology Associates, Cullman, AL," exact="United States," post="5Lincoln, Boulogne-Billancourt, France, 6Genzyme, a Sanofi Company, Cambridge, MA,"/>
  <result pre="States, 5Lincoln, Boulogne-Billancourt, France, 6Genzyme, a Sanofi Company, Cambridge, MA," exact="United States" post="Background: Teriflunomide is a once-daily oral immunomodulator approved for"/>
  <result pre="describe baseline characteristics of patients enrolled in Teri-PRO in the" exact="United States." post="Methods: Teri-PRO is a global, prospective, single-arm, multicenter, open-label"/>
  <result pre="Canada, 2Genzyme, a Sanofi Company, Chilly-Mazarin, France, 3Sanofi, Bridgewater, NJ," exact="United States," post="4University of Toronto, Toronto, ON, Canada Background: Teriflunomide is"/>
  <result pre="3Sanofi, Bridgewater, NJ, United States, 4University of Toronto, Toronto, ON," exact="Canada" post="Background: Teriflunomide is a once-daily oral immunomodulator for the"/>
  <result pre="1University of Texas, Health Science Center at Houston, Houston, TX," exact="United States," post="2Mecklenburg Neurological Associates, Charlotte, NC, United States, 3Advanced Neurological"/>
  <result pre="Houston, Houston, TX, United States, 2Mecklenburg Neurological Associates, Charlotte, NC," exact="United States," post="3Advanced Neurological Specialists, Great Falls, MT, United States, 4Swedish"/>
  <result pre="Charlotte, NC, United States, 3Advanced Neurological Specialists, Great Falls, MT," exact="United States," post="4Swedish Medical Center, Littleton, CO, United States, 5Teva Pharmaceutical"/>
  <result pre="Great Falls, MT, United States, 4Swedish Medical Center, Littleton, CO," exact="United States," post="5Teva Pharmaceutical Industries, Netanya, Israel, 6Teva Pharmaceutical Industries, Frazer,"/>
  <result pre="5Teva Pharmaceutical Industries, Netanya, Israel, 6Teva Pharmaceutical Industries, Frazer, PA," exact="United States," post="7Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany, 8Teva Pharmaceutical Industries, Cleveland,"/>
  <result pre="7Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany, 8Teva Pharmaceutical Industries, Cleveland, OH," exact="United States" post="Background: Improving convenience and patient (pt) experience could support"/>
  <result pre="Pharma AG, Basel, Switzerland, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ," exact="United States" post="Background: Multiple sclerosis (MS) is associated with accelerated brain"/>
  <result pre="1, R Verbeek 1, EH Venneker 1 1Delta Crystallon, Leiden," exact="Netherlands" post="Background: During multiple sclerosis (MS), widespread accumulation occurs of"/>
  <result pre="Department of Neuroscience and Imaging, Chieti, Italy, 7Novartis Farma, Origgio," exact="Italy" post="Background: Fingolimod 0.5 mg was the first oral therapy"/>
  <result pre="J Brady 2, O Kenny 1, K Kinsella 1, S" exact="Jordan" post="1, C McKenna 3, C Muldowney 3, S Basdeo"/>
  <result pre="Hospital, Dublin, Ireland, 7Mater University Hospital, Department of Neurology, Dublin," exact="Ireland" post="Background: Increasing evidence links vitamin D deficiency to both"/>
  <result pre="Düsseldorf, Germany, 2Johns Hopkins University, Department of Neurology, Baltimore, MD," exact="United States," post="3Biogen Idec Inc., Cambridge, MA, United States Background: In"/>
  <result pre="Neurology, Baltimore, MD, United States, 3Biogen Idec Inc., Cambridge, MA," exact="United States" post="Background: In ADVANCE, a randomized, double-blind, 2-year, Phase 3"/>
  <result pre="NTD Study Group, Bonn, Germany, 5Neurologische Klinik, Universität Dresden, Dresden," exact="Germany" post="Background: Fingolimod, a sphingosine 1-phosphate receptor (S1PR) modulator, was"/>
  <result pre="M Starck 1, J Koehler 1 1Marianne Strauss Klinik, Berg," exact="Germany" post="Background: Vitamin D in multiple sclerosis (MS) is still"/>
  <result pre="I Study Investigators 1Mount Sinai Medical Center, New York, NY," exact="United States," post="2Hôpital de la Salpêtrière, Paris, France, 3Genzyme, a Sanofi"/>
  <result pre="la Salpêtrière, Paris, France, 3Genzyme, a Sanofi Company, Cambridge, MA," exact="United States" post="Background: In the phase 3 Comparison of Alemtuzumab and"/>
  <result pre="Group 1University Medical Center, Göttingen, Germany, 2Bayer Pharma AG, Berlin," exact="Germany" post="Background: The BETAPAEDIC study is the first prospective, international,"/>
  <result pre="the CARE-MS I Investigators 1University of Cambridge, Addenbrooke’s Hospital, Cambridge," exact="United Kingdom," post="2Montréal Neurological Institute, McGill University, Department of Neurology and"/>
  <result pre="Center and Department of Biomedical Engineering, Cleveland Clinic, Cleveland, OH," exact="United States," post="4University of Texas Medical Branch, Round Rock, TX, United"/>
  <result pre="United States, 4University of Texas Medical Branch, Round Rock, TX," exact="United States," post="5Heinrich-Heine University, Department of Neurology and Center for Neuropsychiatry,"/>
  <result pre="6First School of Medicine, Charles University, Department of Neurology, Prague," exact="Czech Republic," post="7Medical University of Łódź, Department of Neurology, Łódź, Poland,"/>
  <result pre="of Neurology, Łódź, Poland, 8Genzyme, a Sanofi Company, Cambridge, MA," exact="United States," post="9University of Cambridge, Department of Clinical Neurosciences, Cambridge, United"/>
  <result pre="United States, 9University of Cambridge, Department of Clinical Neurosciences, Cambridge," exact="United Kingdom" post="Background: Alemtuzumab is approved in over 30 countries for"/>
  <result pre="Attitudes of people with multiple sclerosis towards clinical research S" exact="Jordan" post="1, K O’Connell 1, M Duggan 1, N Tubridy"/>
  <result pre="1, C McGuigan 1 1St Vincent’s University Hospital, Neurology, Dublin," exact="Ireland" post="Background: Clinical research remains invaluable in understanding the natural"/>
  <result pre="with multiple sclerosis F Curtin 1 1GeNeuro, Plan les Ouates," exact="Switzerland" post="Background: Human endogenous retrovirus (HERV) genes represent 8% of"/>
  <result pre="4Juntendo University Graduate School of Medicine, Department of Immunology, Bunkyo-ku," exact="Japan" post="Background: We have previously reported that OCH, a sphingosine-truncated"/>
  <result pre="Montreal, QC, Canada, 5First School of Medicine, Charles University, Prague," exact="Czech Republic," post="6Moscow Multiple Sclerosis Center, Moscow, Russian Federation, 7Carolinas Medical"/>
  <result pre="Charles University, Prague, Czech Republic, 6Moscow Multiple Sclerosis Center, Moscow," exact="Russian Federation," post="7Carolinas Medical Center, Charlotte, NC, United States, 8University of"/>
  <result pre="Sclerosis Center, Moscow, Russian Federation, 7Carolinas Medical Center, Charlotte, NC," exact="United States," post="8University of Münster, Münster, Germany, 9University of Utah Medical"/>
  <result pre="Germany, 9University of Utah Medical School, Salt Lake City, UT," exact="United States," post="10Abbvie Biotherapeutics Inc, Redwood City, CA, United States, 11Biogen"/>
  <result pre="City, UT, United States, 10Abbvie Biotherapeutics Inc, Redwood City, CA," exact="United States," post="11Biogen Idec, Cambridge, MA, United States Background: Daclizumab high-yield"/>
  <result pre="Inc, Redwood City, CA, United States, 11Biogen Idec, Cambridge, MA," exact="United States" post="Background: Daclizumab high-yield process (DAC HYP), a humanized monoclonal"/>
  <result pre="1University of Texas Health Science Center at Houston, Houston, TX," exact="United States," post="2Genzyme, a Sanofi Company, Chilly-Mazarin, France, 3Sanofi, Bridgewater, NJ,"/>
  <result pre="States, 2Genzyme, a Sanofi Company, Chilly-Mazarin, France, 3Sanofi, Bridgewater, NJ," exact="United States," post="4Icahn School of Medicine at Mount Sinai, New York,"/>
  <result pre="4Icahn School of Medicine at Mount Sinai, New York, NY," exact="United States" post="Background: TOPIC (NCT00622700) was a phase 3 study to"/>
  <result pre="2Baylor Institute for Immunology Research, Multiple Sclerosis Program, Dallas, TX," exact="United States," post="3Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland"/>
  <result pre="for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH," exact="United States," post="4Biogen Idec Inc., Cambridge, MA, United States Background: Delayed-release"/>
  <result pre="Clinic, Cleveland, OH, United States, 4Biogen Idec Inc., Cambridge, MA," exact="United States" post="Background: Delayed-release dimethyl fumarate (DMF) demonstrated efficacy on clinical"/>
  <result pre="1Comprehensive Multiple Sclerosis Center, Thomas Jefferson University Hospital, Philadelphia, PA," exact="United States," post="2University of Ottawa and the Ottawa Hospital Research Institute,"/>
  <result pre="5Icahn School of Medicine at Mount Sinai, New York, NY," exact="United States," post="6University of Texas Health Science Center at Houston, Houston,"/>
  <result pre="6University of Texas Health Science Center at Houston, Houston, TX," exact="United States," post="7University of Toronto, Toronto, ON, Canada, 8Genzyme, a Sanofi"/>
  <result pre="Canada, 8Genzyme, a Sanofi Company, Chilly-Mazarin, France, 9Sanofi, Bridgewater, NJ," exact="United States," post="10University Vita-Salute San Raffaele, Milan, Italy Background: Teriflunomide is"/>
  <result pre="9Sanofi, Bridgewater, NJ, United States, 10University Vita-Salute San Raffaele, Milan," exact="Italy" post="Background: Teriflunomide is a once-daily oral immunomodulator approved for"/>
  <result pre="Germany, 13Universitätsmedizin Mannheim, University of Heidelberg, Dept. of Neurology, Mannheim," exact="Germany" post="Background: Natalizumab is an intravenously applied humanized monoclonal antibody,"/>
  <result pre="(RRMS) patients, an open-label real-world study is being conducted in" exact="Germany" post="(TRUST). Methods: Biomarkers such as quantitative anti-JCV antibody-status and"/>
  <result pre="The CombiRx Investigators 1University of Alabama at Birmingham, Birmingham, AL," exact="United States," post="2Icahn School of Medicine at Mount Sinai, New York,"/>
  <result pre="2Icahn School of Medicine at Mount Sinai, New York, NY," exact="United States," post="3University of Texas Health Science Center at Houston, Houston,"/>
  <result pre="3University of Texas Health Science Center at Houston, Houston, TX," exact="United States" post="Background: Double-blind trials are designed to reduce bias in"/>
  <result pre="O Khan 8,9 1University of Alabama at Birmingham, Birmingham, AL," exact="United States," post="2University of Texas, Health Science Center at Houston, Houston,"/>
  <result pre="2University of Texas, Health Science Center at Houston, Houston, TX," exact="United States," post="3San Raffaele Scientific Institute and Vita-Salute San Raffaele University,"/>
  <result pre="Pharmaceutical Industries, Petach Tiqva, Israel, 5Teva Pharmaceutical Industries, Frazer, PA," exact="United States," post="6Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany, 7Teva Pharmaceutical Industries, Netanya,"/>
  <result pre="Sclerosis Center, Wayne State University School of Medicine, Detroit, MI," exact="United States," post="9Sastry Foundation Advanced Imaging Laboratory, Wayne State University School"/>
  <result pre="Imaging Laboratory, Wayne State University School of Medicine, Detroit, MI," exact="United States" post="Background: The GALA trial in RRMS showed glatiramer acetate"/>
  <result pre="Pharma AG, Basel, Switzerland, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ," exact="United States" post="Background: In relapsing-remitting multiple sclerosis (RRMS), the presence of"/>
  <result pre="3 1Stony Brook University, Department of Neurology, Stony Brook, NY," exact="United States," post="2EMD Serono, Inc., Rockland, MA, United States, 3University of"/>
  <result pre="Stony Brook, NY, United States, 2EMD Serono, Inc., Rockland, MA," exact="United States," post="3University of Chicago, Chicago, MA, United States Background: EVIDENCE"/>
  <result pre="Inc., Rockland, MA, United States, 3University of Chicago, Chicago, MA," exact="United States" post="Background: EVIDENCE (EVidence of Interferon Dose-response: European North American"/>
  <result pre="II Investigators 1Department of Biomedical Engineering, Cleveland Clinic, Cleveland, OH," exact="United States," post="2VU University Medical Centre, Amsterdam, Netherlands, 3Mellen Center and"/>
  <result pre="Center and Department of Biomedical Engineering, Cleveland Clinic, Cleveland, OH," exact="United States," post="4University of Texas Medical Branch, Round Rock, TX, United"/>
  <result pre="United States, 4University of Texas Medical Branch, Round Rock, TX," exact="United States," post="5Medical University of Łódź, Department of Neurology, Łódź, Poland,"/>
  <result pre="of Neurology, Łódź, Poland, 6Genzyme, a Sanofi Company, Cambridge, MA," exact="United States," post="7NeuroRx Research, Montréal, QC, Canada, 8Department of Neurology and"/>
  <result pre="Canada, 8Department of Neurology and Neurosurgery, Montréal Neurological, Montréal, QC," exact="Canada" post="Background: Alemtuzumab is approved in over 30 countries for"/>
  <result pre="3 1Stony Brook University, Department of Neurology, Stony Brook, NY," exact="United States," post="2EMD Serono, Inc., Rockland, MA, United States, 3University of"/>
  <result pre="Stony Brook, NY, United States, 2EMD Serono, Inc., Rockland, MA," exact="United States," post="3University of Chicago, Chicago, IL, United States Background: Previously,"/>
  <result pre="Inc., Rockland, MA, United States, 3University of Chicago, Chicago, IL," exact="United States" post="Background: Previously, the EVIDENCE (EVidence of Interferon Dose-response: European"/>
  <result pre="of Medicine, Department of Neurosciences, Reproductive and Odontostomatological Sciences, Naples," exact="Italy" post="Background: Palmitoylethanolamide (PEA), the naturally occurring amide of ethanolamine"/>
  <result pre="Dutta 1 1AbbVie, Clinical Pharmacology and Pharmacometrics, North Chicago, IL," exact="United States," post="2Biogen Idec, Clinical Pharmacology and Pharmacometrics, Cambridge, MA, United"/>
  <result pre="United States, 2Biogen Idec, Clinical Pharmacology and Pharmacometrics, Cambridge, MA," exact="United States," post="3AbbVie Biotherapeutics, Redwood City, CA, United States, 4Current address:"/>
  <result pre="Pharmacometrics, Cambridge, MA, United States, 3AbbVie Biotherapeutics, Redwood City, CA," exact="United States," post="4Current address: Genentech, Clinical Pharmacology, San Francisco, CA, United"/>
  <result pre="United States, 4Current address: Genentech, Clinical Pharmacology, San Francisco, CA," exact="United States" post="Background: Daclizumab is an IgG1 monoclonal antibody that inhibits"/>
  <result pre="Dresden, Germany, 2Novartis Pharma GmbH, Nuremberg, Germany, 3Kantar Health, Munich," exact="Germany" post="Background: Once daily oral fingolimod, a sphingosine 1-phosphate receptor"/>
  <result pre="Vincent’s University Hospital, Dublin, Ireland, 2Biogen Idec Inc., Cambridge, MA," exact="United States," post="3Cleveland Clinic, Mellen Center for Multiple Sclerosis Treatment and"/>
  <result pre="Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, OH," exact="United States," post="4St. Josef Hospital, Ruhr University, Bochum, Germany Background: Delayed-release"/>
  <result pre="Cleveland, OH, United States, 4St. Josef Hospital, Ruhr University, Bochum," exact="Germany" post="Background: Delayed-release dimethyl fumarate (DMF) demonstrated efficacy on clinical"/>
  <result pre="M Savelieva 1, E Wallström 1 1Novartis Pharma AG, Basel," exact="Switzerland" post="Background: Siponimod (BAF312), a novel sphingosine 1-phosphate receptor (S1P)-1,5"/>
  <result pre="2Baylor Institute for Immunology Research, Multiple Sclerosis Program, Dallas, TX," exact="United States," post="3McGill University, Montreal Neurological Institute, Montreal, QC, Canada, 4St."/>
  <result pre="Hospital, Basel Neurology, Basel, Switzerland, 6Biogen Idec Inc., Cambridge, MA," exact="United States," post="7Cleveland Clinic, Mellen Center for Multiple Sclerosis Treatment and"/>
  <result pre="Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, OH," exact="United States" post="Background: Oral delayed-release dimethyl fumarate (DMF) demonstrated efficacy and"/>
  <result pre="are reported, as this represents the approved dose in the" exact="United States" post="and the European Union. Results: Of 2,079 patients completing"/>
  <result pre="V Pearson 1, R Girvan 1 1Innate Immunotherapeutics Ltd, Auckland," exact="New Zealand" post="Background: Innate immune modulator, MIS416, is in clinical development"/>
  <result pre="Kappos 2 1Novartis Pharma AG, Basel, Switzerland, 2University Hospital, Basel," exact="Switzerland" post="Background: The efficacy of fingolimod vs placebo on magnetic"/>
  <result pre="D Mikol 1, S Belachew 1 1Biogen Idec, Cambridge, MA," exact="United States," post="2Mellen Center, Cleveland Clinic Foundation, Cleveland, OH, United States"/>
  <result pre="MA, United States, 2Mellen Center, Cleveland Clinic Foundation, Cleveland, OH," exact="United States" post="Background: The Expanded Disability Status Scale (EDSS)-Plus was developed"/>
  <result pre="Italy, 2Mount Sinai School of Medicine, Neurology, New York, NY," exact="United States," post="3New York University, Neurology, New York, NY, United States,"/>
  <result pre="NY, United States, 3New York University, Neurology, New York, NY," exact="United States," post="4Columbia University, Neurology, New York, NY, United States, 5Mount"/>
  <result pre="York, NY, United States, 4Columbia University, Neurology, New York, NY," exact="United States," post="5Mount Sinai School of Medicine, Neuroscience, New York, NY,"/>
  <result pre="States, 5Mount Sinai School of Medicine, Neuroscience, New York, NY," exact="United States," post="6Mount Sinai School of Medicine, Radiology, New York, NY,"/>
  <result pre="States, 6Mount Sinai School of Medicine, Radiology, New York, NY," exact="United States" post="Background: Primary-Progressive Multiple Sclerosis (PP-MS) is characterized by steady"/>
  <result pre="Sapienza, Neurology and Psychiatry, Rome, Italy, 2Santa Lucia Fundation, Rome," exact="Italy" post="Background: In Multiple Sclerosis (MS) the severity of cognitive"/>
  <result pre="UMR 7357, Strasbourg, France, 2Hôpitaux Universitaires de Strasbourg, Neurologie, Strasbourg," exact="France" post="Background: Affective disorders are frequent in multiple sclerosis (MS),"/>
  <result pre="Unit, Institute of Experimental Neurology, Vita-Salute San Raffaele University, Milan," exact="Italy" post="Background: Fatigue is a common and debilitating symptom related"/>
  <result pre="1,2 1Stony Brook University, Department of Neurology, Stony Brook, NY," exact="United States," post="2Lourie Center for Pediatric MS, Stony Brook, NY, United"/>
  <result pre="United States, 2Lourie Center for Pediatric MS, Stony Brook, NY," exact="United States," post="3CogState Inc., &amp;amp; Child Study Center, Yale University School"/>
  <result pre="Study Center, Yale University School of Medicine, New Haven, CT," exact="United States" post="Background: Pediatric-onset MS has an incidence of 0.2 to"/>
  <result pre="5The Children’s Hospital of Philadelphia, Division of Neurology, Philadelphia, PA," exact="United States" post="Background: Information processing speed (IPS) increases with myelination. Decreased"/>
  <result pre="R Zivadinov 4, M Ramanthan 5 1DeltaQuest Foundation, Concord, MA," exact="United States," post="2Tufts University Medical School, Medicine and Orthopaedic Surgery, Boston,"/>
  <result pre="2Tufts University Medical School, Medicine and Orthopaedic Surgery, Boston, MA," exact="United States," post="3Oslo and Akershus University College of Applied Sciences, Nursing,"/>
  <result pre="Oslo, Norway, 4University of Buffalo, Department of Neurology, Buffalo, MA," exact="United States," post="5University of Buffalo, Pharmaceutical Sciences, Buffalo, NY, United States"/>
  <result pre="MA, United States, 5University of Buffalo, Pharmaceutical Sciences, Buffalo, NY," exact="United States" post="Background: Neurological reserve has been implicated as a possible"/>
  <result pre="Mainero 1,2 1AA Martinos Center For Biomedical Imaging, Charlestown, MA," exact="United States," post="2Harvard University, Boston, MA, United States, 3Beth Israel Deaconess"/>
  <result pre="Biomedical Imaging, Charlestown, MA, United States, 2Harvard University, Boston, MA," exact="United States," post="3Beth Israel Deaconess Medical Center, Boston, MA, United States,"/>
  <result pre="MA, United States, 2Harvard University, Boston, MA, United States, 3Beth" exact="Israel" post="Deaconess Medical Center, Boston, MA, United States, 4Virginia Mason"/>
  <result pre="MA, United States, 3Beth Israel Deaconess Medical Center, Boston, MA," exact="United States," post="4Virginia Mason Medical Center, Seattle, WA, United States, 5Ecole"/>
  <result pre="Boston, MA, United States, 4Virginia Mason Medical Center, Seattle, WA," exact="United States," post="5Ecole Polytechnique de Montréal, Montreal, QC, Canada Background: Cortical"/>
  <result pre="Seattle, WA, United States, 5Ecole Polytechnique de Montréal, Montreal, QC," exact="Canada" post="Background: Cortical lesions are a major determinant of impaired"/>
  <result pre="Psychology, Ottawa, ON, Canada, 3The Ottawa Hospital, Medicine, Ottawa, ON," exact="Canada" post="Background: Cognitive fatigue (CF) can be defined as an"/>
  <result pre="1,2 1Stony Brook University, Department of Neurology, Stony Brook, NY," exact="United States," post="2Lourie Center for Pediatric MS, Stony Brook, NY, United"/>
  <result pre="United States, 2Lourie Center for Pediatric MS, Stony Brook, NY," exact="United States" post="Background: The possibility of cognitive impairment is a major"/>
  <result pre="Montreal, QC, Canada, 5McGill University, Neurology and Neurosurgery, Montreal, QC," exact="Canada" post="Background: Recent findings from modeling cognitive impairment in people"/>
  <result pre="2Royal Holloway, University of London, Department of Clinical Psychology, Surrey," exact="United Kingdom" post="Background: Cognitive impairment is common in MS irrespective of"/>
  <result pre="G Losinski 1, B Mamone 1 1Cleveland Clinic, Cleveland, OH," exact="United States" post="Background: The 10/36 Spatial Memory Test (10/36) is widely"/>
  <result pre="Chieti, Italy, 10Hospital of Gallarate, Gallarate, Italy, 11Villa Mazzacorati, Bologna," exact="Italy" post="Background: The BICAMS (Brief International Cognitive Assessment for Multiple"/>
  <result pre="Baycrest, Toronto, ON, Canada, 5Children’s Hospital of Philadelphia, Philadelphia, PA," exact="United States" post="Background: The Symbol Digit Modalities Test (SDMT) is a"/>
  <result pre="Hospital, Department of Neurology and Center of Clinical Neuroscience, Prague," exact="Czech Republic," post="2School of Medicine and Biomedical Sciences, University at Buffalo,"/>
  <result pre="York, Buffalo Neuroimaging Analysis Center, Department of Neurology, Buffalo, NY," exact="United States," post="3IRCCS &quot;S.Maria Nascente&quot;, Don Gnocchi Foundation, Milan, Italy, 4Melbourne"/>
  <result pre="of Medicine and General University Hospital, Department of Radiology, Prague," exact="Czech Republic," post="7School of Medicine and Biomedical Sciences, University at Buffalo,"/>
  <result pre="New York, MR Imaging Clinical Translational Research Center, Buffalo, NY," exact="United States" post="Background: Cognitive impairment (CI) may occur in clinically isolated"/>
  <result pre="Hospital, Department of Neurology and Center of Clinical Neuroscience, Prague," exact="Czech Republic," post="2School of Medicine and Biomedical Sciences, University at Buffalo,"/>
  <result pre="York, Buffalo Neuroimaging Analysis Center, Department of Neurology, Buffalo, NY," exact="United States," post="3IRCCS &quot;S.Maria Nascente&quot;, Don Gnocchi Foundation, Milan, Italy, 4Charles"/>
  <result pre="of Medicine and General University Hospital, Department of Radiology, Prague," exact="Czech Republic," post="5School of Medicine and Biomedical Sciences, University at Buffalo,"/>
  <result pre="New York, MR Imaging Clinical Translational Research Center, Buffalo, NY," exact="United States" post="Background: Repeated administration of Paced Auditory Serial Addition Test-3"/>
  <result pre="1,2 1Yeshiva University, Ferkauf Graduate School of Psychology, Bronx, NY," exact="United States," post="2Holy Name Medical Center Multiple Sclerosis Center, Teaneck, NJ,"/>
  <result pre="States, 2Holy Name Medical Center Multiple Sclerosis Center, Teaneck, NJ," exact="United States" post="Background: Cognitive impairment has been estimated to affect 45-65%"/>
  <result pre="Psychology, Ottawa, ON, Canada, 4The Ottawa Hospital, Neurology, Ottawa, ON," exact="Canada" post="Background: The Brief International Cognitive Assessment for MS (BICAMS)"/>
  <result pre="M Turatti 2, S Forlivesi 1, F Gobbin 1, S" exact="Monaco" post="1, MD Benedetti 3 1University of Verona, Dpt of"/>
  <result pre="del Garda, Italy, 3Azienda Ospedaliera Universitaria Integrata, Neurology Unit, Verona," exact="Italy" post="Background: Benign multiple sclerosis (BMS) definition is generally based"/>
  <result pre="1,2 1Stony Brook University, Department of Neurology, Stony Brook, NY," exact="United States," post="2Lourie Center for Pediatric MS, Stony Brook, NY, United"/>
  <result pre="United States, 2Lourie Center for Pediatric MS, Stony Brook, NY," exact="United States" post="Background: Information processing speed is a common area of"/>
  <result pre="Department, Barcelona, Spain, 2Hospital Universitario Virgen Macarena, Neurology Department, Sevilla," exact="Spain" post="Background: The Brief Repeatable Battery of Neuropsychological tests (BRB-N)"/>
  <result pre="Standard. Results: 291 RRMS patients from 21 Neurology Departments in" exact="Spain" post="were included. The mild disability group (EDSS 0-3) included"/>
  <result pre="Vechta, Germany, 4University of Cologne, Psychology, Cologne, Germany, 5Merck-Serono, Darmstadt," exact="Germany" post="Background: Cognitive and psychoaffective disturbances may present already in"/>
  <result pre="about 2 to 2,5 hours. Currently, 2 study sites in" exact="Austria" post="and 22 study sites in Germany are registered. Results:"/>
  <result pre="2 study sites in Austria and 22 study sites in" exact="Germany" post="are registered. Results: A first analysis of the clinicometric"/>
  <result pre="Toronto, ON, Canada, 7Children’s Hospital of Philadelphia, Neurology, Philadelphia, PA," exact="United States," post="8York University, Psychology, Toronto, ON, Canada Background: Acute CNS"/>
  <result pre="Neurology, Philadelphia, PA, United States, 8York University, Psychology, Toronto, ON," exact="Canada" post="Background: Acute CNS demyelination occurs in 0.9 per 100,000"/>
  <result pre="AB, Canada, 3Dalhousie University, Psychology and Neuroscience, Psychiatry, Halifax, NS," exact="Canada" post="Background: Impairments in attention and information processing speed are"/>
  <result pre="Canada, 5University of Pennsylvania, Children’s Hospital of Philadelphia, Philadelphia, PA," exact="United States" post="Background: Pediatric-onset multiple sclerosis (MS) is often accompanied by"/>
  <result pre="of Ottawa, Ottawa, ON, Canada, 3The Ottawa Hospital, Ottawa, ON," exact="Canada" post="Background: The Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) is a"/>
  <result pre="DeLuca 1,2,3, G Wylie 1,2,4 1Kessler Foundation, West Orange, NJ," exact="United States," post="2Rutgers New Jersey Medical School, Physical Medicine and Rehabilitation,"/>
  <result pre="1,2,4 1Kessler Foundation, West Orange, NJ, United States, 2Rutgers New" exact="Jersey" post="Medical School, Physical Medicine and Rehabilitation, Newark, NJ, United"/>
  <result pre="New Jersey Medical School, Physical Medicine and Rehabilitation, Newark, NJ," exact="United States," post="3Rutgers New Jersey Medical School, Neurology &amp;amp; Neurosciences, Newark,"/>
  <result pre="Physical Medicine and Rehabilitation, Newark, NJ, United States, 3Rutgers New" exact="Jersey" post="Medical School, Neurology &amp;amp; Neurosciences, Newark, NJ, United States,"/>
  <result pre="3Rutgers New Jersey Medical School, Neurology &amp;amp; Neurosciences, Newark, NJ," exact="United States," post="4War Related Illness &amp;amp; Injury Study Center, Department of"/>
  <result pre="Injury Study Center, Department of Veterans Affairs, East Orange, NJ," exact="United States" post="Background: Fatigue is perhaps the most common complaint associated"/>
  <result pre="Children, Toronto, ON, Canada, 4Children’s Hospital of Philadelphia, Philadelphia, PA," exact="United States" post="Background: Inhibitory control, defined as the ability to withhold"/>
  <result pre="Canada, 3Children’s Hospital of Philadelphia, Dept. of Neurology, Philadelphia, PA," exact="United States" post="Background: Cognitive impairment is reported to occur in 30"/>
  <result pre="2, J Herbert 2 1Yeshiva University, Pscyhology, New York, NY," exact="United States," post="2New York University School of Medicine, Neurology, New York,"/>
  <result pre="2New York University School of Medicine, Neurology, New York, NY," exact="United States" post="Background: The corpus callosum, a heavily myelinated tract connecting"/>
  <result pre="Bordeaux, France, 4Brigham &amp;amp; Women’s Hospital, Neurological Imaging, Boston, MA," exact="United States," post="5Université de Bordeaux &amp;amp; CHU de Bordeaux, Bordeaux, France"/>
  <result pre="United States, 5Université de Bordeaux &amp;amp; CHU de Bordeaux, Bordeaux," exact="France" post="Background: Clinically isolated syndromes (CIS) could be associated with"/>
  <result pre="Clinic, Ottawa, ON, Canada, 5University of Ottawa, Neurology, Ottawa, ON," exact="Canada" post="Background: The Computerized Test of Information Processing (CTIP) is"/>
  <result pre="S Gierer 1 1Neurologische Gemeinschaftspraxis Dillingen, Dillingen an der Donau," exact="Germany" post="Background: MS patients suffering from physical disability, fatigue, cognitive"/>
  <result pre="1Institute for Neurological Research Dr. Raúl Carrea (FLENI), Buenos Aires," exact="Argentina" post="Background: Cognitive impairment can be present early on in"/>
  <result pre="J Sloan 1, FW Foley 1,2 1Yeshiva University, Bronx, NY," exact="United States," post="2Holy Name Medical Center, Teaneck, NJ, United States Background:"/>
  <result pre="Bronx, NY, United States, 2Holy Name Medical Center, Teaneck, NJ," exact="United States" post="Background: Cognitive dysfunction is a frequently occurring symptom of"/>
  <result pre="2University of Newcastle, Newcastle, Australia, 3John Hunter Hospital, Neurology, Newcastle," exact="Australia" post="Background: Cognitive impairment is common in MS and occurs"/>
  <result pre="Medicine, Oslo, Norway, 3University of Oslo, Institute of Psychology, Oslo," exact="Norway" post="Background: Self-reported episodic memory may be affected in relapsing"/>
  <result pre="INSERM U 862, Bordeaux, France, 2CHU de Bordeaux, Neurology, Bordeaux," exact="France" post="Background: Assessment of cognitive impairment (CI) in persons with"/>
  <result pre="Psychiatry, Rome, Italy, 2S. Andrea Hospital, Physical Therapy Unit, Rome," exact="Italy" post="Background: Deficits in attention and executive function processes have"/>
  <result pre="Bruce 1 1University of Missouri-Kansas City, Psychology, Kansas City, MO," exact="United States," post="2Avila University, Psychology, Independence, MO, United States, 3University of"/>
  <result pre="Kansas City, MO, United States, 2Avila University, Psychology, Independence, MO," exact="United States," post="3University of Kansas Medical Center, Kansas City, KS, United"/>
  <result pre="United States, 3University of Kansas Medical Center, Kansas City, KS," exact="United States" post="Background: Information processing speed and auditory verbal memory are"/>
  <result pre="Columbia, Vancouver, BC, Canada, 5Capital District Health Authority, Halifax, NS," exact="Canada" post="Background: Cognitive impairments are common among persons with multiple"/>
  <result pre="1, SG Lynch 2 1University of Kansas, Psychology, Lawrence, KS," exact="United States," post="2University of Kansas Medical Center, Neurology, Kansas City, KS,"/>
  <result pre="States, 2University of Kansas Medical Center, Neurology, Kansas City, KS," exact="United States," post="3University of Kansas Medical Center, Molecular and Integrative Physiology,"/>
  <result pre="Kansas Medical Center, Molecular and Integrative Physiology, Kansas City, KS," exact="United States," post="4University of Kansas Medical Center, Hoglund Brain Imaging Center,"/>
  <result pre="Kansas Medical Center, Hoglund Brain Imaging Center, Kansas City, KS," exact="United States" post="Background: Accumulating evidence points to neurodegeneration as the primary"/>
  <result pre="Sciences, Ribeirão Preto, Brazil, 2Brazilian Institute of Neuroscience (IBNeuro), Brasília," exact="Brazil" post="Background: The WMS-IV is gold standard in memory assessment."/>
  <result pre="Laguna, Spain, 2Hospital Universitario de Canarias, Research Unit, La Laguna," exact="Spain" post="Background: Cognitive impairment affects 43-75% of the patients with"/>
  <result pre="School of Medicine, Gold Coast, Australia, 7University of Newcastle, Newcastle," exact="Australia" post="Background: Cognition is impaired in multiple sclerosis (MS) even"/>
  <result pre="Centre, London, ON, Canada, 3St. Joseph’s Health Care, London, ON," exact="Canada" post="Background: Cognitive impairment (CI) is known to be a"/>
  <result pre="4Ospedale Fatebenefratelli, Isola Tiberina, Rome, Italy, 5Università ‘Tor Vergata’, Rome," exact="Italy" post="Background: Impaired executive functioning can be present since early"/>
  <result pre="1Research Institute and Hospital of National Cancer Center, Neurology, Go-Yang," exact="Korea, Republic of," post="2Research Institute and Hospital of National Cancer Center, Mental"/>
  <result pre="and Hospital of National Cancer Center, Mental Health Clinic, Go-Yang," exact="Korea, Republic of," post="3The Catholic University of Korea, Neurology, Seoul, Korea, Republic"/>
  <result pre="Korea, Republic of, 3The Catholic University of Korea, Neurology, Seoul," exact="Korea, Republic of" post="Background: A few studies have recently reported that about"/>
  <result pre="Hospital, Giresun, Turkey, 3Dokuz Eylul University, Dept. of Neurology, Izmir," exact="Turkey" post="Background: As would be expected a substantial number of"/>
  <result pre="Canada, 4Children’s Hospital of Philadelphia, Dept. of Neurology, Philadelphia, PA," exact="United States" post="Background: Working memory (WM) dysfunction is common amongst patients"/>
  <result pre="S Gierer 1 1Neurologische Gemeinschaftspraxis Dillingen, Dillingen an der Donau," exact="Germany" post="Background: Although there is a reasonable intersection of fatigue"/>
  <result pre="Amsterdam, Netherlands, 2VU University Medical Center, Epidemiology and Biostatistics, Amsterdam," exact="Netherlands" post="Background: The Symbol Digit Modalities Test (SDMT) has been"/>
  <result pre="Hospital, Department of Neurology and Center of Clinical Neuroscience, Prague," exact="Czech Republic," post="2Charles University in Prague, First Faculty of Medicine and"/>
  <result pre="of Medicine and General University Hospital, Department of Radiology, Prague," exact="Czech Republic" post="Background: Atrophy of corpus callosum is an important predictor"/>
  <result pre="1,3 1Yeshiva University, Ferkauf Graduate School of Psychology, Bronx, NY," exact="United States," post="2NYU School of Medicine, Department of Psychiatry, New York,"/>
  <result pre="2NYU School of Medicine, Department of Psychiatry, New York, NY," exact="United States," post="3Holy Name Medical Center, Teaneck, NJ, United States, 4NYU"/>
  <result pre="York, NY, United States, 3Holy Name Medical Center, Teaneck, NJ," exact="United States," post="4NYU School of Medicine, Department of Rehabilitation Medicine, New"/>
  <result pre="School of Medicine, Department of Rehabilitation Medicine, New York, NY," exact="United States" post="Background: MS is an autoimmune disorder that is more"/>
  <result pre="Psychology, Division of Neuropsychology, Zurich, Switzerland, 4Medizinisch Radiologisches Institut, Zurich," exact="Switzerland" post="Background: By now, cortical involvement in Multiple Sclerosis (MS)"/>
  <result pre="Lisboa (ISCTE-IUL), Lisboa, Portugal, 2Hospital S. João, Neurology Department, Porto," exact="Portugal" post="Background: Cognitive impairment (CI) is known to be high"/>
  <result pre="of Ottawa, Division of Neurology, Faculty of Medicine, Ottawa, ON," exact="Canada" post="Background: The Computerized Test of Information Processing (CTIP) consists"/>
  <result pre="Lille, France, 4Universite Catholique de Lille, Faculté de Medecine, Lille," exact="France" post="Background: Cognitive impairment in Multiple Sclerosis (MS) is one"/>
  <result pre="2, J DeLuca 2 1New York University, New York, NY," exact="United States," post="2Kessler Foundation, West Orange, NJ, United States Background: To"/>
  <result pre="New York, NY, United States, 2Kessler Foundation, West Orange, NJ," exact="United States" post="Background: To date, most studies of the Symbol Digit"/>
  <result pre="Medicine, Oslo, Norway, 12Haukeland University Hospital, Department of Neurology, Bergen," exact="Norway" post="Background: Smoking is a risk factor for MS and"/>
  <result pre="Danish Multiple Sclerosis Registry, The Danish MS Research Center, Copenhagen," exact="Denmark" post="Background: Smoking increases the risk of MS and disease"/>
  <result pre="Medicine, Stockholm, Sweden, 2Karolinska Institutet, Department of Clinical Neuroscience, Stockholm," exact="Sweden" post="Background: Environmental risk factors influencing MS risk include a"/>
  <result pre="Raffals 3, OH Kantarci 1 1Mayo Clinic, Neurology, Rochester, MN," exact="United States," post="2International Clinical Research Center, St. Anne’s University Hospital Brno,"/>
  <result pre="2International Clinical Research Center, St. Anne’s University Hospital Brno, Brno," exact="Czech Republic," post="3Mayo Clinic, Gastroenterology and Hepatology, Rochester, MN, United States,"/>
  <result pre="Brno, Czech Republic, 3Mayo Clinic, Gastroenterology and Hepatology, Rochester, MN," exact="United States," post="4Mayo Clinic, Division of Biomedical Statistics and Informatics, Rochester,"/>
  <result pre="4Mayo Clinic, Division of Biomedical Statistics and Informatics, Rochester, MN," exact="United States" post="Background: Anti-TNFα therapy can induce remission in inflammatory bowel"/>
  <result pre="Canada, 5University of Alberta, Faculty of Rehabiliation Medicine, Edmonton, AB," exact="Canada" post="Background: While much is known about the use of"/>
  <result pre="1Novartis Pharma AG, Basel, Switzerland, 2Novartis Pharma Co. Ltd, Shanghai," exact="China" post="Background: Limited data are available regarding comorbidities in patients"/>
  <result pre="Spain, 4Hospital Universitario de Canarias, Servicio de Neurofisiología, La Laguna," exact="Spain" post="Background: Sleep disorders are seen in patients with demyelinating"/>
  <result pre="1,2,3 1Jacobs Comprehensive MS Treatment and Research Center, Buffalo, NY," exact="United States," post="2New York State MS Consortium, Buffalo, NY, United States,"/>
  <result pre="NY, United States, 2New York State MS Consortium, Buffalo, NY," exact="United States," post="3State University of New York at Buffalo, Department of"/>
  <result pre="of New York at Buffalo, Department of Neurology, Buffalo, NY," exact="United States," post="4Buffalo Neuroimaging Analysis Center, Department of Neurology, Buffalo, NY,"/>
  <result pre="States, 4Buffalo Neuroimaging Analysis Center, Department of Neurology, Buffalo, NY," exact="United States" post="Background: Although there seems to be growing evidence of"/>
  <result pre="M Goldacre 2 1University of Oxford, John Radcliffe Hospital, Oxford," exact="United Kingdom," post="2University of Oxford, Unit of Health-Care Epidemiology, Nuffield Department"/>
  <result pre="Unit of Health-Care Epidemiology, Nuffield Department of Population Health, Oxford," exact="United Kingdom," post="3Queen Mary University of London, Barts and the London"/>
  <result pre="the London School of Medicine and Dentistry, Blizard Institute, London," exact="United Kingdom" post="Background: Few studies have investigated the relationship between alcohol"/>
  <result pre="3Sheba Medical Center, Pediatric Endocrinology, Ramat Gan, Israel, 4Medistat, Tel-Aviv," exact="Israel" post="Background: Scarce information is available about the association of"/>
  <result pre="of Clinical Neuroscience, School of Medicine, University of Nottingham, Nottingham," exact="United Kingdom," post="2Division of Child Health, Obstetrics and Gynaecology, School of"/>
  <result pre="Obstetrics and Gynaecology, School of Medicine, University of Nottingham, Nottingham," exact="United Kingdom," post="3Division of Paediatric Neurology and Paediatric General Medicine, Chang"/>
  <result pre="Orthopaedics and Dermatology, School of Medicine, University of Nottingham, Nottingham," exact="United Kingdom," post="5Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial"/>
  <result pre="and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, Republic of" exact="China" post="Background: Comorbidities in individuals with multiple sclerosis (MS) may"/>
  <result pre="Hospital, Rigshospitalet, Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen," exact="Denmark" post="Background: Recent studies found evidence that systemic inflammation and"/>
  <result pre="Portugal, 2Faculty of Medicine, University of Coimbra, Portugal, Neurology, Coimbra," exact="Portugal" post="Background: Multiple sclerosis (MS) is a chronic inflammatory demyelinating"/>
  <result pre="Nicholas 2,3 1Ohio State University College of Medicine, Columbus, OH," exact="United States," post="2Ohio State University, Department of Neurology, Columbus, OH, United"/>
  <result pre="United States, 2Ohio State University, Department of Neurology, Columbus, OH," exact="United States," post="3Ohio State University Multiple Sclerosis Center, Columbus, OH, United"/>
  <result pre="United States, 3Ohio State University Multiple Sclerosis Center, Columbus, OH," exact="United States," post="4Ohio State University, Department of Biostatistics, Columbus, OH, United"/>
  <result pre="United States, 4Ohio State University, Department of Biostatistics, Columbus, OH," exact="United States" post="Background: Patients with multiple sclerosis (MS) have been shown"/>
  <result pre="Canada, 6Division of Neurology, Children’s Hospital of Philadelphia, Philadelphia, PA," exact="United States" post="Background: Overweight and obesity in childhood and early adolescence"/>
  <result pre="B Weinstock-Guttman 3, RH Benedict 3 1DeltaQuest Foundation, Concord, MA," exact="United States," post="2Tufts University Medical School, Medicine and Orthopaedic Surgery, Boston,"/>
  <result pre="2Tufts University Medical School, Medicine and Orthopaedic Surgery, Boston, MA," exact="United States," post="3University of Buffalo, Department of Neurology, Buffalo, MA, United"/>
  <result pre="United States, 3University of Buffalo, Department of Neurology, Buffalo, MA," exact="United States," post="4University of Rochester Medical Center, Psychiatry, Rochester, NY, United"/>
  <result pre="United States, 4University of Rochester Medical Center, Psychiatry, Rochester, NY," exact="United States," post="5University of Rochester Medical Center, Rochester Health Care Decision"/>
  <result pre="Medical Center, Rochester Health Care Decision Making Group, Rochester, NY," exact="United States" post="Background: Neurological reserve may slow disease progression in multiple"/>
  <result pre="University of New York, Buffalo Neuroimaging Analysis Center, Buffalo, NY," exact="United States," post="2State University of New York at Buffalo, Neurology, Buffalo,"/>
  <result pre="2State University of New York at Buffalo, Neurology, Buffalo, NY," exact="United States" post="Background: While concomitant diseases occur in association with multiple"/>
  <result pre="Herbert 1,2 1Barnabas Multiple Sclerosis Comprehensive Care Center, Livingston, NJ," exact="United States," post="2NYU Medical Center, New York, NY, United States Background:"/>
  <result pre="Livingston, NJ, United States, 2NYU Medical Center, New York, NY," exact="United States" post="Background: CVID is the most common primary immunodeficiency diagnosed"/>
  <result pre="Medical Center, Multiple Sclerosis Center, Ramat Gan, Israel, 4Medistat, Tel-Aviv," exact="Israel" post="Background: We hypothesized that multiple sclerosis (MS) patients with"/>
  <result pre="Promotion, Roma, Italy, 4CRS4, Technology Park, Distributed Computing Group, Pula," exact="Italy" post="Background: People with Multiple Sclerosis (MS) report lower levels"/>
  <result pre="National and Kapodistrian University, Department of Neurology, ‘Aeginition’ Hospital, Athens," exact="Greece" post="Background: The incidence and prevalence of ischemic heart disease"/>
  <result pre="of California San Francisco, School of Medicine, San Francisco, CA," exact="United States," post="24University of Cambridge, Department of Clinical Neurosciences, Cambridge, United"/>
  <result pre="United States, 24University of Cambridge, Department of Clinical Neurosciences, Cambridge," exact="United Kingdom," post="25University of Oslo, Department of Molecular Biology, Oslo, Norway"/>
  <result pre="United Kingdom, 25University of Oslo, Department of Molecular Biology, Oslo," exact="Norway" post="Background: Immunological hallmarks of multiple sclerosis (MS) are production"/>
  <result pre="Millis 1, O Khan 1 1Wayne State University, Detroit, MI," exact="United States" post="Background: CSF oligoclonal bands (OCB) are one of immunopathologic"/>
  <result pre="Germany, 10University of Rostock, Rostock, Germany, 11University of Leipzig, Leipzig," exact="Germany" post="Background: The majority of patients presenting with a clinically"/>
  <result pre="Methods: Patients were recruited from 10 specialized MS centers in" exact="Germany" post="and Austria. Inclusion criteria were discharge diagnosis of CIS,"/>
  <result pre="Health, National Institute of Neurological Disorders and Stroke, Bethesda, MD," exact="United States" post="Background: We have previously reported that daclizumab (DAC), a"/>
  <result pre="1 1University of Colorado School of Medicine, Neurology, Aurora, CO," exact="United States" post="Background: Multiple sclerosis (MS) is a chronic inflammatory disease"/>
  <result pre="T Wu 1, B Bielekova 1 1NIH, NINDS, Bethesda, MD," exact="United States" post="Background: Lack of therapeutic efficacy of immunomodulatory therapies in"/>
  <result pre="2, E Evdoshenko 2 1First Pavlov State Medical University, Saint-Petersburg," exact="Russian Federation," post="2Saint-Petersburg City Clinical Hospital #31, Saint-Petersburg Center MS and"/>
  <result pre="Clinical Hospital #31, Saint-Petersburg Center MS and Autoimmune Diseases, Saint-Petersburg," exact="Russian Federation" post="Background: Increased intrathecal synthesis of immunoglobulins and oligoclonal synthesis"/>
  <result pre="1 1University of Colorado Anschutz Medical Campus, Neurology, Aurora, CO," exact="United States," post="2University of Colorado Anschutz Medical Campus, Neurosurgery, Aurora, CO,"/>
  <result pre="States, 2University of Colorado Anschutz Medical Campus, Neurosurgery, Aurora, CO," exact="United States" post="Background: Multiple sclerosis (MS) is a chronic inflammatory disease"/>
  <result pre="3Hospital Clínico Universitario, Unit of Neuroimmunology - Neurology Department, Valencia," exact="Spain" post="Background: The presence of lipid-specific IgM oligoclonal bands in"/>
  <result pre="Santa Lucia/Centro Europeo per la Ricerca sul Cervello (CERC), Rome," exact="Italy" post="Background: Pathogenic events leading to brain structural damage in"/>
  <result pre="Eylul University, Biology, Izmir, Turkey, 4Dokuz Eylul University, Radiology, Izmir," exact="Turkey" post="Background: The presence of oligoclonal bands (OCBs) in cerebrospinal"/>
  <result pre="4Hospital Universitari i Politècnic La Fe, Laboratory of Immunology, Valencia," exact="Spain" post="Background: The presence of lipid-specific oligoclonal IgM bands (LS-OCMB)"/>
  <result pre="Obesidad y la Nutrición (CIBERobn, CB06/03), Department of Diabetes, Girona," exact="Spain" post="Background: Multiple sclerosis (MS) is associated with both physical"/>
  <result pre="4Hospital Clínic de Barcelona, MS Unit - Neurology Department, Barcelona," exact="Spain" post="Background: The spectrum of chronic relapsing inflammatory demyelinating diseases"/>
  <result pre="Neurologia 2 - Centro Riferimento Regionale Sclerosi Multipla (CRESM), Orbassano," exact="Italy" post="Background: AAN Guidelines (2005) suggest the use of 22"/>
  <result pre="Erlangen, Germany, 3University of Manchester, Institute of Population Health, Manchester," exact="United Kingdom," post="4University of Witten/Herdecke, Centre of Paediatrics and Youth Medicine,"/>
  <result pre="Neuropediatrics, Heidelberg, Germany, 13University of Würzburg, Department of Neuropediatrics, Würzburg," exact="Germany" post="Background: Isolated optic neuritis (ON) in childhood may remain"/>
  <result pre="Turkey, 3Dokuz Eylul University, Izmir, Turkey, 4Usak State Hospital, Usak," exact="Turkey" post="Background: Intrathecally synthesised IgM can be seen not only"/>
  <result pre="Cajal para la Investigación Sanitaria (IRYCIS), Departments of Immunology, Madrid," exact="Spain" post="Background: Multiple Sclerosis (MS) is an inflammatory, demyelinating and"/>
  <result pre="JL Frederiksen 1 1Glostrup Hospital, University of Copenhagen, Neurology, Glostrup," exact="Denmark" post="Background: Multiple Sclerosis (MS) patients typically have a characteristic"/>
  <result pre="1 1University of Colorado School of Medicine, Neurology, Aurora, CO," exact="United States," post="2University of Colorado School of Medicine, Neurosurgery, Aurora, CO,"/>
  <result pre="States, 2University of Colorado School of Medicine, Neurosurgery, Aurora, CO," exact="United States," post="3University of Colorado School of Medicine, Webb-Waring Center, Aurora,"/>
  <result pre="3University of Colorado School of Medicine, Webb-Waring Center, Aurora, CO," exact="United States" post="Background: A characteristic feature of the CNS inflammatory response"/>
  <result pre="Smagina 1, S Elchaninova 1 1Altai State Medical University, Barnaul," exact="Russian Federation" post="Background: The prediction of Multiple Sclerosis (MS) relapses and"/>
  <result pre="Informatics, Management and Ethics (LIME), Stockholm, Sweden, 3Carmona AB, Halmstad," exact="Sweden" post="Background: MS patient registries with longitudinally collected data are"/>
  <result pre="Z Xia 4,5 1Harvard University, Department of Statistics, Cambridge, MA," exact="United States," post="2Brigham and Women’s Hospital, Department of Neurology, Boston, MA,"/>
  <result pre="States, 2Brigham and Women’s Hospital, Department of Neurology, Boston, MA," exact="United States," post="3Harvard School of Public Health, Department of Biostatistics, Boston,"/>
  <result pre="3Harvard School of Public Health, Department of Biostatistics, Boston, MA," exact="United States," post="4Brigham and Women’s Hospital, Program in Translational NeuroPsychiatric Genomics,"/>
  <result pre="Program in Translational NeuroPsychiatric Genomics, Department of Neurology, Boston, MA," exact="United States," post="5Harvard Medical School, Boston, MA, United States Background: Comorbid"/>
  <result pre="Neurology, Boston, MA, United States, 5Harvard Medical School, Boston, MA," exact="United States" post="Background: Comorbid conditions can impact disease outcome and course"/>
  <result pre="Neurology - Multiple Sclerosis Comprehensive Care Center, New York, NY," exact="United States," post="2Georgetown University Hospital, Neurology, Washington, DC, United States, 3Rocky"/>
  <result pre="York, NY, United States, 2Georgetown University Hospital, Neurology, Washington, DC," exact="United States," post="3Rocky Mountain MS Clinic, Salt Lake City, UT, United"/>
  <result pre="United States, 3Rocky Mountain MS Clinic, Salt Lake City, UT," exact="United States," post="4University of Buffalo, Neurology, Buffalo, NY, United States, 5Barnabas"/>
  <result pre="City, UT, United States, 4University of Buffalo, Neurology, Buffalo, NY," exact="United States," post="5Barnabas Health MS Center, Neurology, Livingston, NJ, United States,"/>
  <result pre="NY, United States, 5Barnabas Health MS Center, Neurology, Livingston, NJ," exact="United States," post="6University of Texas Southwestern Medical Center, Neurology, Dallas, TX,"/>
  <result pre="States, 6University of Texas Southwestern Medical Center, Neurology, Dallas, TX," exact="United States," post="7National Institue of Neurological Disease and Stroke, Bethesda, MD,"/>
  <result pre="States, 7National Institue of Neurological Disease and Stroke, Bethesda, MD," exact="United States," post="8National Institue of Allergy and Immunology, Bethesda, MD, United"/>
  <result pre="United States, 8National Institue of Allergy and Immunology, Bethesda, MD," exact="United States," post="9University of Alabama at Birmingham, Birmingham, AL, United States"/>
  <result pre="MD, United States, 9University of Alabama at Birmingham, Birmingham, AL," exact="United States" post="Background: Natalizumab (NTZ) is a highly effective treatment approved"/>
  <result pre="1New York University School of Medicine, Neurology, New York, NY," exact="United States," post="2Amiri Hospital, Kuwait, Kuwait, 3Karadeniz Technical University Farabi Hospital,"/>
  <result pre="Hospital, Hobart, Australia, 10Mayis University, Samsun, Turkey, 11Westmead Hospital, Sydney," exact="Australia" post="Background: Longitudinal study of a rare disease is challenging"/>
  <result pre="M Golberg 14, A Castronuovo 1, Real Study Group 1Novartis" exact="Argentina" post="SA, Medical, Buenos Aires, Argentina, 2Office, Buenos Aires, Argentina,"/>
  <result pre="Blanca, Argentina, 14Office, La Plata, Argentina, 15Office, Santiago del Estero," exact="Argentina" post="Background: Once-daily oral fingolimod (Gilenya) is approved in Argentina"/>
  <result pre="Estero, Argentina Background: Once-daily oral fingolimod (Gilenya) is approved in" exact="Argentina" post="for the treatment of relapsing multiple sclerosis (MS) since"/>
  <result pre="label study enrolling 200 RRMS patients in 30 centers in" exact="Argentina" post="receiving fingolimod to treat the disease. All patients currently"/>
  <result pre="Hospital, Örebro, Sweden, 9Danderyd Hospital, Department of Clinical Science, Stockholm," exact="Sweden" post="Background: Natalizumab (NTZ) is a disease modulatory treatment for"/>
  <result pre="in the real-world setting. Therefore, when NTZ was launched in" exact="Sweden" post="in August 2006, the &quot;Immunomodulation and Multiple Sclerosis Epidemiology&quot;"/>
  <result pre="of NTZ in a real-world setting. Methods: MS patients in" exact="Sweden" post="are registered into the nationwide web-based Swedish MS registry"/>
  <result pre="SM Kim 1 1Yonsei University College of Medicine, Neurology, Seoul," exact="Korea, Republic of," post="2Kangbuk Samsung Hospital, Neurology, Seoul, Korea, Republic of, 3Catholic"/>
  <result pre="Neurology, Seoul, Korea, Republic of, 2Kangbuk Samsung Hospital, Neurology, Seoul," exact="Korea, Republic of," post="3Catholic University of Korea, Neurology, Seoul, Korea, Republic of"/>
  <result pre="Seoul, Korea, Republic of, 3Catholic University of Korea, Neurology, Seoul," exact="Korea, Republic of" post="Background: Transverse myelitis (TM) can appear as the first"/>
  <result pre="Lotze 1,2 1Baylor College of Medicine, Pediatric Neurology, Houston, TX," exact="United States," post="2Texas Children Hospital, Pediatric Neurology, Houston, TX, United States,"/>
  <result pre="TX, United States, 2Texas Children Hospital, Pediatric Neurology, Houston, TX," exact="United States," post="3Baylor College of Medicine, Department of Molecular and Human"/>
  <result pre="of Medicine, Department of Molecular and Human Genetics, Houston, TX," exact="United States" post="Background: Neuromyelitis optica (NMO) is typified by optic neuritis"/>
  <result pre="Germany, 7University Hospital Heidelberg, Neurology, Devision of Molecular Neuroimmunology, Heidelberg," exact="Germany" post="Background: Susac syndrome (SuS) is a rare, presumably autoimmune-mediated"/>
  <result pre="2, HJ Kim 3 1Dongguk University Ilsan Hospital, Neurology, Goyang-si," exact="Korea, Republic of," post="2Sungkyunkwan University Samsung Seoul Hospital, Neurology, Seoul, Korea, Republic"/>
  <result pre="Korea, Republic of, 2Sungkyunkwan University Samsung Seoul Hospital, Neurology, Seoul," exact="Korea, Republic of," post="3National Cancer Center, Neurology, Goyang-si, Korea, Republic of Background:"/>
  <result pre="Neurology, Seoul, Korea, Republic of, 3National Cancer Center, Neurology, Goyang-si," exact="Korea, Republic of" post="Background: Neuromyelitis optica (NMO) is an inflammatory demyelinating condition"/>
  <result pre="Rouen, Rouen, France, 4CHU Caen, Caen, France, 5CHU Strasbourg, Strasbourg," exact="France" post="Background: Recently, the International Panel on Diagnosis of Multiple"/>
  <result pre="Centre, London, ON, Canada, 3Lawson Health Research Institute, London, ON," exact="Canada" post="Background: Multiple Sclerosis (MS) can demonstrate a benign or"/>
  <result pre="Medicine, Berlin, Germany, 7Institute of Neuroradiology, University Medicine Goettingen, Goettingen," exact="Germany" post="Background: Baló’s concentric sclerosis (Baló) is a rare variant"/>
  <result pre="Sendai, Japan, 7Federal University of Minas Gerais, Neurology, Belo Horizonte," exact="Brazil" post="Background: Longitudinally extensive spinal cord lesions on the magnetic"/>
  <result pre="Unit, Milan, Italy, 4San Raffaele Hospital, Neuroimaging Research Unit, Milan," exact="Italy" post="Background: The early identification of patients at risk of"/>
  <result pre="Network 1University of Oxford, Nuffield Department of Clinical Neurosciences, Oxford," exact="United Kingdom," post="2Oxford University Hospitals NHS Trust, Department of Neurology, Oxford,"/>
  <result pre="Kingdom, 2Oxford University Hospitals NHS Trust, Department of Neurology, Oxford," exact="United Kingdom," post="3Medical University of Graz, Department of Neurology, Graz, Austria,"/>
  <result pre="Department of Radiology, Barcelona, Spain, 6UCL Institute of Neurology, London," exact="United Kingdom," post="7University of Siena, Department of Neurological and Behavioural Sciences,"/>
  <result pre="Copenhagen, Denmark, 10St Josef Hospital Ruhr-University, Department of Radiology, Bochum," exact="Germany" post="Background: Mitochondrial dysfunction may play an important role in"/>
  <result pre="of Liège, Liège, Belgium, 3University Hospital of Liège, Neurology, Liège," exact="Belgium" post="Background: Walking impairment is frequent and appears early in"/>
  <result pre="Health Clinical and Molecular Medicine, Cagliari, Italy, 18Cardiff University, Cardiff," exact="United Kingdom," post="19Policlinico Gemelli, Rome, Italy, 20Azienda Ospedaliera S. Andrea, Rome,"/>
  <result pre="Italy, 21Ospedale San Raffaele, Milano, Italy, 22Ospedale PA Micone, Genova," exact="Italy" post="Background: Since the first appearance of McDonald’s diagnostic criteria"/>
  <result pre="China, 4The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou," exact="China" post="Background: Deep gray matter lesions(DGMLs) and deep white matter"/>
  <result pre="Hospital, Neurology, Algiers, Algeria, 2Institut Pasteur of Algeria, Immunology, Algiers," exact="Algeria" post="Background: Multiple Sclerosis (MS) is the most common demyelinating"/>
  <result pre="Hospital, Bordeaux, France, 6Universitary Hospital, Caen, France, 7Universitary Hospital, Strasbourg," exact="France" post="Background: Isolated tumefactive inflammatory lesions can rarely reveal MS."/>
  <result pre="2Alexandria, Alexandria, Egypt, 3Alexandria, Radiology, Alexandria, Egypt, 4Aexandria, Neurology, Alexandria," exact="Egypt" post="Background: Proton MR spectroscopy (1H-MR spectroscopy) is a well-established"/>
  <result pre="Artal 1, H Mourao Mesquita 2 1Raigmore Hospital, Neurology, Inverness," exact="United Kingdom," post="2Matsumoto Medical Center, Neurology, Brasilia, Brazil Background: Human T-cell"/>
  <result pre="Hospital, Neurology, Inverness, United Kingdom, 2Matsumoto Medical Center, Neurology, Brasilia," exact="Brazil" post="Background: Human T-cell lymphotropic virus 1 (HTLV-1) associated myelopathy/tropical"/>
  <result pre="1Kafkas University Medical Faculty, Neurology, Kars, Turkey, 2Trakya University, Edirne," exact="Turkey" post="Background: Microscopic polyangiitis (MPA) is a systemic inflammatory disease"/>
  <result pre="Clinic MS Care Center Clinical Trials Site Hanka Hertmanowska, Plewiska," exact="Poland" post="Background: Borrelia burgdorferi (BB) is a bacterial species of"/>
  <result pre="ON, Canada, 3St. Michael’s Hospital, Division of Neurology, Toronto, ON," exact="Canada" post="Background: Tumefactive demyelinating lesions (TDLs) occur in a rare"/>
  <result pre="Neurochemistry, Mölndal, Sweden, 4Institute of Neurology, University College London, London," exact="United Kingdom" post="Background: Several CSF biomarkers have been suggested as prognostic"/>
  <result pre="4, TB Tomasi 2 1SUNY University at Buffalo, Buffalo, NY," exact="United States," post="2Roswell Park Institute, Buffalo, NY, United States, 3SUNY University"/>
  <result pre="Buffalo, Buffalo, NY, United States, 2Roswell Park Institute, Buffalo, NY," exact="United States," post="3SUNY University at Buffalo, Pharmaceutical Sciences, Buffalo, NY, United"/>
  <result pre="United States, 3SUNY University at Buffalo, Pharmaceutical Sciences, Buffalo, NY," exact="United States," post="4SUNY University at Buffalo, Neurology, Buffalo, NY, United States"/>
  <result pre="NY, United States, 4SUNY University at Buffalo, Neurology, Buffalo, NY," exact="United States" post="Background: miRNA-mediated regulation of gene expression is an important"/>
  <result pre="Achiron 1 1Sheba Medical Center, Multiple Sclerosis Center, Ramat Gan," exact="Israel" post="Background: Interferon-beta is the recommended immunomodulatory treatment for the"/>
  <result pre="‘International Clinically Isolated Syndrome Consortium (iCIS)’ 1Queen Mary University, London," exact="United Kingdom," post="2Vita-Salute San Raffaele University, Milan, Italy, 3Erasmus MC University"/>
  <result pre="Center, Rotterdam, Netherlands, 4City Clinical Hospital # 31, St Petersburg," exact="Russian Federation," post="5Université Montpellier 1, Montpellier, France, 6University of Bari, Bari,"/>
  <result pre="Sweden, 8University Hospital, Basel, Switzerland, 9VU University Medical Centre, Amsterdam," exact="Netherlands" post="Background: Neurofilaments (Nf) are highly specific structural elements of"/>
  <result pre="1, T Luider 1, R Hintzen 1 1Erasmus MC, Rotterdam," exact="Netherlands" post="Background: A few percent of all multiple sclerosis (MS)"/>
  <result pre="1 1Johns Hopkins University School of Medicine, Neurology, Baltimore, MD," exact="United States," post="2Johns Hopkins University School of Medicine, Pathology, Baltimore, MD,"/>
  <result pre="States, 2Johns Hopkins University School of Medicine, Pathology, Baltimore, MD," exact="United States" post="Background: Multiple Sclerosis (MS) is a chronic demyelinating disorder"/>
  <result pre="MS Center, Rigshospitalet, University of Copenhagen, Dept of Neurology, Copenhagen," exact="Denmark" post="Background: Cerebrospinal fluid (CSF) levels of inflammatory biomarkers have"/>
  <result pre="F Dicuonzo 1, M Trojano 1 1University of Bari, Bari," exact="Italy" post="Background: MRI measures are known surrogate markers of disease"/>
  <result pre="Nebraska-Lincoln, School of Veterinary Medicine and Biomedical Sciences, Lincoln, NE," exact="United States" post="Background: The demyelinating diseases comprise a broad spectrum of"/>
  <result pre="Denmark, 3Aarhus University Hospital, Department of Clinical Biochemestry, Aarhus C," exact="Denmark" post="Background: Biomarkers for Multiple Sclerosis (MS) are needed for"/>
  <result pre="1, N Monson 1 1University of Texas Southwestern, Dallas, TX," exact="United States," post="2DioGenix, Gaithersburg, MD, United States Background: Multiple Sclerosis is"/>
  <result pre="of Texas Southwestern, Dallas, TX, United States, 2DioGenix, Gaithersburg, MD," exact="United States" post="Background: Multiple Sclerosis is known to be an autoimmune"/>
  <result pre="University Hospital, Multiple Sclerosis Centre of Catalonia, Neuroimmunology Department, Barcelona," exact="Spain" post="Background: Multiple sclerosis (MS) is one of the leading"/>
  <result pre="Hungary, 6Uppsala University, Science for Life Laboratory (SciLife Lab), Uppsala," exact="Sweden" post="Background: Multiple sclerosis (MS) is a demyelinative disorder of"/>
  <result pre="Pharmacology and Clinical Neuroscience, Umeå, Sweden, 2Uman Diagnostics AB, Umeå," exact="Sweden" post="Background: Neurofilament light (NFL) is an integral part of"/>
  <result pre="Medicina Molecolare e Biotecnologie, Milano, Italy, 2University of Milano, Milano," exact="Italy" post="Background: Activation of the innate immune response is mediated"/>
  <result pre="Neurology, Amsterdam, Netherlands, 3University Hospital Basel, Department of Biomedicine, Basel," exact="Switzerland" post="Background: The patho-physiology of multiple sclerosis disease onset and"/>
  <result pre="T Luider 1, RQ Hintzen 1 1Erasmus MC, Neurology, Rotterdam," exact="Netherlands" post="Background: In recent studies we have shown the validity"/>
  <result pre="1Tisch MS Research Center of New York, New York, NY," exact="United States" post="Background: Identification of biomarkers for diagnosis and therapeutic monitoring"/>
  <result pre="Greece, 2Aristotle University, Papanikolaou Hospital, 3rd Department of Neurology, Thessaloniki," exact="Greece" post="Background: Several cerebrospinal fluid (CSF) proteins have been studied"/>
  <result pre="1 1Brigham and Women’s Hospital, Harvard Medical School, Boston, MA," exact="United States," post="2EMD Serono Inc., Billerica, MA, United States Background: 8-Isoprostane"/>
  <result pre="School, Boston, MA, United States, 2EMD Serono Inc., Billerica, MA," exact="United States" post="Background: 8-Isoprostane (8-iso-PGF 2α or 15-F 2t-IsoP) is a"/>
  <result pre="Yang 1, D Cadavid 1 1Biogen Idec, Inc., Cambridge, MA," exact="United States" post="Background: BIIB033, a fully human IgG1 monoclonal antibody that"/>
  <result pre="Izmir, Turkey, 3Ege University Medical School of Hospital, Ophthalmology, Izmir," exact="Turkey" post="Background: Neurofilaments (Nf) are promising candidate to be a"/>
  <result pre="of Texas Health Science Center at Houston, Neurology, Houston, TX," exact="United States," post="2University of Texas Health Science Center at Houston, Biomedical"/>
  <result pre="Texas Health Science Center at Houston, Biomedical Informatics, Houston, TX," exact="United States," post="3University of Texas Health Science Center at Houston, Integrative"/>
  <result pre="Science Center at Houston, Integrative Biology and Pharmacology, Houston, TX," exact="United States" post="Background: Exacerbations or relapses are a typical clinical feature"/>
  <result pre="Poznan, Poland, 5Adam Mickiewicz University, Department of Macromolecular Physics, Poznan," exact="Poland" post="Background: Nuclear Magnetic Resonance (NMR) spectroscopy identifies metabolites of"/>
  <result pre="Australia, 4Hunter Area Pathology Service, Division of Molecular Genetics, Newcastle," exact="Australia" post="Background: The role of microRNAs (miRNA) in multiple sclerosis"/>
  <result pre="Clerici 1 1Don C. Gnocchi Foundation, Lab Molecular Medicine, Milano," exact="Italy" post="Background: Clinical progression of multiple sclerosis (MS) is correlated"/>
  <result pre="2Imperial College, Department of Primary Care and Public Health, London," exact="United Kingdom," post="3University Federico II, Department of Public Health, Napoli, Italy"/>
  <result pre="United Kingdom, 3University Federico II, Department of Public Health, Napoli," exact="Italy" post="Background: Multiple sclerosis (MS) pathogenesis represents a significant challenge"/>
  <result pre="University Hospital, Multiple Sclerosis Centre of Catalonia, Neuroimmunology Department, Barcelona," exact="Spain" post="Background: Multiple Sclerosis (MS) is a neurodegenerative immune-mediated disease"/>
  <result pre="3Vall Hebron University Hospital, Magnetic Resonance Unit, Neuroradiology Department, Barcelona," exact="Spain" post="Background: Neurofilament light (NfL) subunit levels in cerebrospinal fluid"/>
  <result pre="Sendai, Japan, 8Tohoku University, Department of Multiple Sclerosis Therapeutics, Sendai," exact="Japan" post="Background: Neuromyelitis optica (NMO) is characterized by severe optic"/>
  <result pre="(TDD), Neuro-Behcet’s disease). Methods: We conducted multicentric cross-sectional study in" exact="Japan" post="from January 1999 to December 2012 including 129 patients"/>
  <result pre="1Tisch MS Research Center of New York, New York, NY," exact="United States" post="Background: There is a need for accurate and predictable"/>
  <result pre="4University &quot;G. d’Annunzio&quot;, School of Medicine and Health Sciences, Chieti," exact="Italy" post="Background: A very active field of research in MS"/>
  <result pre="MG Marrosu 1 1University of Cagliari, Cagliari, Italy, 2ASL8, Cagliari," exact="Italy" post="Background: Multiple sclerosis (MS) is a chronic disease of"/>
  <result pre="P Sacchetta 1, P Del Boccio 1 1G. d’Annunzio, Chieti," exact="Italy" post="Background: Multiple Sclerosis (MS) is a disease due to"/>
  <result pre="M Jovanovic 1, A Jovicic 1 1Military Medical Academy, Belgrade," exact="Serbia" post="Background: Oxidative stress is proposed as one of possible"/>
  <result pre="Lucas 1, G Izquierdo Ayuso 1 1Hospital Virgen Macarena, Seville," exact="Spain" post="Background: Interferon therapy decreases the plasma concentration of reduced"/>
  <result pre="Institute, University of Minho, Braga, Portugal, 3ICVS/3B’s Associated Laboratory, Braga," exact="Portugal" post="Background: Lipocalin-2 (LCN2) is small molecule secreted by neutrophils"/>
  <result pre="Obesidad y la Nutrición (CIBERobn, CB06/03), Department of Diabetes, Girona," exact="Spain" post="Background: Multiple Sclerosis (MS) is an inflammatory, demyelinating and"/>
  <result pre="H. San Raffaele, Gallarate-Milan, Italy, 2Centro Studi Sclerosi Multipla, Gallarate," exact="Italy" post="Background: Comparative data are not available on the effectiveness"/>
  <result pre="Glaser 1, J Hillert 1 1Karolinska Institutet, Clinical Neuroscience, Stockholm," exact="Sweden" post="Background: One of the major questions concerning the clinical"/>
  <result pre="B Zeskind 1, I Grossman 2 1Immuneering Corporation, Cambridge, MA," exact="United States," post="2Teva Pharmaceutical Industries Ltd., Petach Tikva, Israel Background: Since"/>
  <result pre="Cambridge, MA, United States, 2Teva Pharmaceutical Industries Ltd., Petach Tikva," exact="Israel" post="Background: Since the 1990s, branded glatiramer acetate (GA) has"/>
  <result pre="studies, especially given that Probioglat is in clinical use in" exact="Mexico" post="where healthcare providers have already reported different responses to"/>
  <result pre="Medical Group, Los Angeles Medical Center, Neurology, Los Angeles, CA," exact="United States," post="2Kaiser Permanente Southern California, Research &amp;amp; Evaluation, Pasadena, CA,"/>
  <result pre="States, 2Kaiser Permanente Southern California, Research &amp;amp; Evaluation, Pasadena, CA," exact="United States" post="Background: Withdrawal from natalizumab treatment in relapsing-remitting multiple sclerosis"/>
  <result pre="Melbourne, Melbourne, Australia, 21Royal Melbourne Hospital, Department of Neurology, Melbourne," exact="Australia" post="Background: Fingolimod has been demonstrated to be superior (i)"/>
  <result pre="relapses), higher number of previous treatment starts and residence in" exact="Australia" post="or Turkey. The 477 (IFN/GA) and 149 (fingolimod) matched"/>
  <result pre="2Vall Hebron University Hospital, Preventive Medicine and Epidemiology Department, Barcelona," exact="Spain" post="Background: Clinical markers of long-term disability in RRMS patients"/>
  <result pre="C Ionete 1 1University of Massachusetts Medical School, Worcester, MA," exact="United States," post="2Maine Medical Center, Portland, ME, United States Background: While"/>
  <result pre="School, Worcester, MA, United States, 2Maine Medical Center, Portland, ME," exact="United States" post="Background: While mitoxantrone is the only FDA-approved drug to"/>
  <result pre="E Frohman 6 1NYU Langone Medical Center, New York, NY," exact="United States," post="2Georgetown University Hospital, Neurology, Washington, DC, United States, 3Rocky"/>
  <result pre="York, NY, United States, 2Georgetown University Hospital, Neurology, Washington, DC," exact="United States," post="3Rocky Mountain MS Clinic, Salt Lake City, UT, United"/>
  <result pre="United States, 3Rocky Mountain MS Clinic, Salt Lake City, UT," exact="United States," post="4University of Buffalo, Neurology, Buffalo, NY, United States, 5Barnabas"/>
  <result pre="City, UT, United States, 4University of Buffalo, Neurology, Buffalo, NY," exact="United States," post="5Barnabas Health MS Center, Neurology, Livingston, NJ, United States,"/>
  <result pre="NY, United States, 5Barnabas Health MS Center, Neurology, Livingston, NJ," exact="United States," post="6University of Texas Southwestern Medical Center, Neurology, Dallas, TX,"/>
  <result pre="States, 6University of Texas Southwestern Medical Center, Neurology, Dallas, TX," exact="United States," post="7National Institute of Neurological Disease and Stroke, Bethesda, MD,"/>
  <result pre="States, 7National Institute of Neurological Disease and Stroke, Bethesda, MD," exact="United States," post="8National Institute of Allergy and Immunology, Bethesda, MD, United"/>
  <result pre="United States, 8National Institute of Allergy and Immunology, Bethesda, MD," exact="United States," post="9University of Alabama at Birmingham, Birmingham, AL, United States"/>
  <result pre="MD, United States, 9University of Alabama at Birmingham, Birmingham, AL," exact="United States" post="Background: Natalizumab (NTZ) is a highly-effective agent approved for"/>
  <result pre="Department of Neurology, Melbourne, Australia, 3Charles University in Prague, Prague," exact="Czech Republic," post="4University of Bari, Bari, Italy, 5University ‘G. d’Annunzio, Chieti,"/>
  <result pre="27Petz A. County Hospital, Gyor, Hungary, 28Karadeniz Technical University, Trabzon," exact="Turkey" post="Background: Patients suffering from breakthrough disease despite treatment with"/>
  <result pre="Pharma AG, Basel, Switzerland, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ," exact="United States," post="3IMS Health, Waltham, MA, United States Background: Persistence with"/>
  <result pre="Corporation, East Hanover, NJ, United States, 3IMS Health, Waltham, MA," exact="United States" post="Background: Persistence with disease-modifying therapies (DMTs) improves clinical outcomes"/>
  <result pre="of California San Francisco, Department of Neurology, San Francisco, CA," exact="United States," post="6University of Genoa, Biostatistics Unit, Department of Health Sciences,"/>
  <result pre="Pharma AG, Basel, Switzerland, 8Novartis Pharmaceuticals Corporation, East Hanover, NJ," exact="United States," post="9University Hospital Basel, Basel, Switzerland Background: Brain volume loss"/>
  <result pre="Corporation, East Hanover, NJ, United States, 9University Hospital Basel, Basel," exact="Switzerland" post="Background: Brain volume loss (BVL) is an established marker"/>
  <result pre="Sclerosis Registry, Copenhagen, Denmark, 3Bayer HealthCare Pharmaceuticals, New Jersey, NJ," exact="United States," post="4University of Chicago Medical Center, Dept. of Neurology, Chicago,"/>
  <result pre="4University of Chicago Medical Center, Dept. of Neurology, Chicago, IL," exact="United States" post="Background: The 21-year long-term follow-up of survival in patients,"/>
  <result pre="Vergata University, Neurosciences, Rome, Italy, 5S. Camillo-Forlanini Hospital, Neurosciences, Rome," exact="Italy" post="Background: Natalizumab is a very effective treatment to prevent"/>
  <result pre="Salzburg, Austria, 5Innsbruck Medical University, Clinical Department of Neurology, Innsbruck," exact="Austria" post="Background: High efficacy of Natalizumab and Fingolimod in the"/>
  <result pre="Medical Faculty, Neurology, Istanbul, Turkey, 2Istanbul Bilim University, Neurology, Istanbul," exact="Turkey" post="Background: There is an obvious need for head-to-head treatment"/>
  <result pre="A Miller 4, A Ally 5 1Georgetown University, Washington, DC," exact="United States," post="2Baylor Research Institute, Dallas, TX, United States, 3Wayne State"/>
  <result pre="University, Washington, DC, United States, 2Baylor Research Institute, Dallas, TX," exact="United States," post="3Wayne State University, Detroit, MI, United States, 4Mount Sinai"/>
  <result pre="Institute, Dallas, TX, United States, 3Wayne State University, Detroit, MI," exact="United States," post="4Mount Sinai School of Medicine, New York, NY, United"/>
  <result pre="United States, 4Mount Sinai School of Medicine, New York, NY," exact="United States," post="5CVS Caremark Inc., Woonsocket, RI, United States Background: A"/>
  <result pre="New York, NY, United States, 5CVS Caremark Inc., Woonsocket, RI," exact="United States" post="Background: A robust, up-to-date treatment algorithm for multiple sclerosis"/>
  <result pre="Sinai Rehabilitation Hospital, Mandell Center for Multiple Sclerosis, Hartford, CT," exact="United States" post="Background: Interferon Beta-1a (IFNB-1a) is routinely prescribed to persons"/>
  <result pre="MG Marrosu 1 1University of Cagliari, Cagliari, Italy, 2ASL8, Cagliari," exact="Italy" post="Background: Multiple sclerosis (MS) is a disease of the"/>
  <result pre="Neurology, Würzburg, Germany, 2University of Münster, Department of Neurology, Münster," exact="Germany" post="Background: Immunotherapy of patients with active secondary progressive multiple"/>
  <result pre="and Mental Health, Toronto, ON, Canada, 2DeltaQuest Foundation, Concord, MA," exact="United States," post="3Tufts University Medical School, Boston, MA, United States, 4Oslo"/>
  <result pre="Concord, MA, United States, 3Tufts University Medical School, Boston, MA," exact="United States," post="4Oslo and Akershus University College of Applied Sciences, Oslo,"/>
  <result pre="Sciences, Oslo, Norway, 5Hospital for Sick Children, Neurology, Toronto, ON," exact="Canada" post="Background: Poor medication adherence occurs in approximately ¼ to"/>
  <result pre="Ontaneda 2 1Cleveland Clinic Lerner College of Medicine, Cleveland, OH," exact="United States," post="2Cleveland Clinic Mellen Center, Cleveland, OH, United States Background:"/>
  <result pre="Cleveland, OH, United States, 2Cleveland Clinic Mellen Center, Cleveland, OH," exact="United States" post="Background: Fingolimod (FTY) and dimethyl fumarate (DMF) are two"/>
  <result pre="PV Soares 1 1Hospital São Francisco, Neurology, Rio de Janeiro," exact="Brazil" post="Background: Current MS therapies target inflammatory activity of disease,"/>
  <result pre="Amersfoort, Netherlands, 16Tweesteden Ziekenhuis, Tilburg, Netherlands, 17MS4 Research Institute, Nijmegen," exact="Netherlands" post="Background: Pulses of high dose intravenous methylprednisolone (IVMP) 500-1000"/>
  <result pre="treated with IVMP were enrolled at 15 hospitals in the" exact="Netherlands" post="from January 2013 until 10 March 2014 (cut-off). The"/>
  <result pre="1, A Camac 1 1Lahey Clinic/Tufts University, Neurology, Lexington, MA," exact="United States" post="Background: Dimethyl fumarate (DMF) is a new oral disease"/>
  <result pre="C Watson 2 1Truven Health Analytics, Outcomes Research, Cambridge, MA," exact="United States," post="2Biogen Idec Inc., HE&amp;amp;OR, Global Market Access, Cambridge, MA,"/>
  <result pre="States, 2Biogen Idec Inc., HE&amp;amp;OR, Global Market Access, Cambridge, MA," exact="United States" post="Background: A recent study conducted using multiple sclerosis (MS)"/>
  <result pre="matched MS patients treating with platform therapy or natalizumab using" exact="United States" post="administrative claims data. Methods: Adults with a diagnosis of"/>
  <result pre="Idec GmbH, Ismaning, Germany, 5Heinrich-Heine University, Department of Neurology, Düsseldorf," exact="Germany" post="Background: Patients with multiple sclerosis (MS) frequently discontinue treatment"/>
  <result pre="1University of Texas, Health Science Center at Houston, Houston, TX," exact="United States," post="2Teva Pharmaceutical Industries, Netanya, Israel, 3Teva Pharmaceutical Industries, Frazer,"/>
  <result pre="2Teva Pharmaceutical Industries, Netanya, Israel, 3Teva Pharmaceutical Industries, Frazer, PA," exact="United States," post="4Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany, 5Teva Pharmaceutical Industries, Cleveland,"/>
  <result pre="4Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany, 5Teva Pharmaceutical Industries, Cleveland, OH," exact="United States" post="Background: Injection site reactions (ISRs) are the most common"/>
  <result pre="3, R Sasane 1 1Novartis Pharmaceuticals Corporation, East Hanover, NJ," exact="United States," post="2Thomas Jefferson University, Jefferson School of Population Health, Philadelphia,"/>
  <result pre="2Thomas Jefferson University, Jefferson School of Population Health, Philadelphia, PA," exact="United States," post="3Analysis Group, Inc., New York, NY, United States, 4Analysis"/>
  <result pre="Philadelphia, PA, United States, 3Analysis Group, Inc., New York, NY," exact="United States," post="4Analysis Group, Inc., Boston, MA, United States Background: Disease"/>
  <result pre="New York, NY, United States, 4Analysis Group, Inc., Boston, MA," exact="United States" post="Background: Disease modifying therapies (DMTs) are the mainstay treatment"/>
  <result pre="Texas Medical Branch, Central Texas Neurology Consultants, Round Rock, TX," exact="United States," post="2Suncoast Neuroscience Associates, St. Petersburg, FL, United States, 3Neurological"/>
  <result pre="Rock, TX, United States, 2Suncoast Neuroscience Associates, St. Petersburg, FL," exact="United States," post="3Neurological Physicians of Arizona, Gilbert, AZ, United States, 4PharmStats,"/>
  <result pre="Petersburg, FL, United States, 3Neurological Physicians of Arizona, Gilbert, AZ," exact="United States," post="4PharmStats, Ltd., Escondido, CA, United States, 5Biogen Idec, Inc.,"/>
  <result pre="of Arizona, Gilbert, AZ, United States, 4PharmStats, Ltd., Escondido, CA," exact="United States," post="5Biogen Idec, Inc., Cambridge, MA, United States Background: Delayed-release"/>
  <result pre="Ltd., Escondido, CA, United States, 5Biogen Idec, Inc., Cambridge, MA," exact="United States" post="Background: Delayed-release dimethyl fumarate (DMF) demonstrated efficacy and safety"/>
  <result pre="1Portland Veterans’ Affairs Medical Center, Neuroimmunology Research, R&amp;amp;D-31, Portland, OR," exact="United States," post="2Oregon Health &amp;amp; Science University, Portland, OR, United States"/>
  <result pre="OR, United States, 2Oregon Health &amp;amp; Science University, Portland, OR," exact="United States" post="Background: CD74, the cell surface form of the MHC"/>
  <result pre="1NYU Langone Multiple Sclerosis Care Center, Neurology, New York, NY," exact="United States" post="Background: Oral dimethyl fumarate (DMF) is approved in the"/>
  <result pre="States Background: Oral dimethyl fumarate (DMF) is approved in the" exact="United States" post="for the treatment of relapsing forms of multiple sclerosis"/>
  <result pre="Turkey, 3Dokuz Eylul University, Izmir, Turkey, 4Usak State Hospital, Usak," exact="Turkey" post="Background: Although some conflicting results, there are some evidences"/>
  <result pre="use in relapsing-remitting and secondary progressive multiple sclerosis in the" exact="United States" post="HJ Gross 1, C Watson 2 1Kantar Health, Princeton,"/>
  <result pre="HJ Gross 1, C Watson 2 1Kantar Health, Princeton, NJ," exact="United States," post="2Biogen Idec Inc., Cambridge, MA, United States Background: Some"/>
  <result pre="Health, Princeton, NJ, United States, 2Biogen Idec Inc., Cambridge, MA," exact="United States" post="Background: Some patients with relapsing-remitting multiple sclerosis (RRMS) subsequently"/>
  <result pre="indicated for relapsing forms of multiple sclerosis (MS) in the" exact="United States" post="(US) has increased over the years, the utilization of"/>
  <result pre="Medicine, Stockholm, Sweden, 2Karolinska Institutet, Department of Clinical Neuroscience, Stockholm," exact="Sweden" post="Background: Natalizumab (NTZ) and fingolimod (FGL) are mainly used"/>
  <result pre="Spain, 3Hospital Francesc De Borja De Gandia, Neurology Department, Gandia," exact="Spain" post="Background: Rituximab (RTX) is an anti-CD20 monoclonal antibody approved"/>
  <result pre="MS Network AlSacEP 1Hôpital de Hautepierre, Strasbourg, France, 2alSacEP, Colmar," exact="France" post="Background: Fingolimod is the first oral therapy for patient"/>
  <result pre="1Partners Pediatric Multiple Sclerosis Centre, Massachusetts General Hospital, Boston, MA," exact="United States," post="2Novartis Pharma AG, Basel, Switzerland, 3Centro Studi Sclerosi Multipla,"/>
  <result pre="Multipla, Gallarate, Italy, 4Children’s Hospital of Eastern Ontario, Ottawa, ON," exact="Canada" post="Background: Relapse and MRI activity have been reported to"/>
  <result pre="Taneja 5, MK Siddiqui 5 1Tolley Health Economics Ltd, Buxton," exact="United Kingdom," post="2St. Vincent’s University Hospital, Dublin, Ireland, 3Geisel School of"/>
  <result pre="Dublin, Ireland, 3Geisel School of Medicine at Dartmouth, Hanover, NH," exact="United States," post="4Biogen Idec Inc., Cambridge, MA, United States, 5HERON™ Commercialization"/>
  <result pre="Dartmouth, Hanover, NH, United States, 4Biogen Idec Inc., Cambridge, MA," exact="United States," post="5HERON™ Commercialization - A Parexel® Company, Chandigarh, India Background:"/>
  <result pre="MA, United States, 5HERON™ Commercialization - A Parexel® Company, Chandigarh," exact="India" post="Background: Peginterferon beta-1a (PEG-IFN; 125 µg every 2 weeks"/>
  <result pre="by Health Technology Assessment bodies in the UK (NICE) and" exact="Germany" post="(IQWiG). The NMA was conducted using WinBUGS (v1.4.3) with"/>
  <result pre="2 1Erciyes University, Neurology, Kayseri, Turkey, 2Erciyes University, Radiology, Kayseri," exact="Turkey" post="Background: MR imaging is the most sensitive and important"/>
  <result pre="Juan MS Center, Caribbean Center for Clinical Research, San Juan," exact="Puerto Rico" post="Background: Fingolimod (FG) is a sphingosine-1-phosphate (S1P) receptor modulator"/>
  <result pre="1 1AXDEV Group, Brossard, QC, Canada, 2Colchester University Hospital, Colchester," exact="United Kingdom" post="Background: The unpredictable nature of multiple sclerosis (MS) creates"/>
  <result pre="Results: The total sample included 148 actively practicing neurologists from" exact="Germany" post="(n=22), Spain (n=22), France (n=23), the United Kingdom (n=23),"/>
  <result pre="total sample included 148 actively practicing neurologists from Germany (n=22)," exact="Spain" post="(n=22), France (n=23), the United Kingdom (n=23), Italy (n=22)"/>
  <result pre="included 148 actively practicing neurologists from Germany (n=22), Spain (n=22)," exact="France" post="(n=23), the United Kingdom (n=23), Italy (n=22) and the"/>
  <result pre="practicing neurologists from Germany (n=22), Spain (n=22), France (n=23), the" exact="United Kingdom" post="(n=23), Italy (n=22) and the United States (n=36). Eighty"/>
  <result pre="Germany (n=22), Spain (n=22), France (n=23), the United Kingdom (n=23)," exact="Italy" post="(n=22) and the United States (n=36). Eighty percent of"/>
  <result pre="France (n=23), the United Kingdom (n=23), Italy (n=22) and the" exact="United States" post="(n=36). Eighty percent of neurologists had a caseload of"/>
  <result pre="Tel-Aviv, Israel, 3Sheba Medical Center, Multiple Sclerosis Center, Ramat Gan," exact="Israel" post="Background: Fingolimod (Gilenya) has shown efficacy in reducing relapses"/>
  <result pre="Arquitecto Marcide, Ferrol, Spain, 8Hospital de Monforte, Monforte de Lemos," exact="Spain" post="Background: Fingolimod is a treatment for relapsing-remitting multiple sclerosis"/>
  <result pre="of Neurology, Foggia, Italy, 3IRCCS Meuromed, Department of Neurology, Pozzilli," exact="Italy" post="Background: To evaluate efficacy of second-line treatments (natalizumab and"/>
  <result pre="- HUG, Département de Pathologie et Immunologie - CMU, Geneva," exact="Switzerland" post="Background: Multiple sclerosis (MS) is more common among women,"/>
  <result pre="Barcelona, Spain, 26Hospital Regional Universitario de Málaga, Neurology Department, Málaga," exact="Spain" post="Background: The aim of the Spanish Gilenya Registry is"/>
  <result pre="1Cantonal Hospital of St. Gallen, Department of Neurology, St. Gallen," exact="Switzerland" post="Background: Cognitive impairment (CI) affects up to 65% of"/>
  <result pre="Hospital/Multiple Sclerosis Clinic/ULB, Neurology, Uccle, Belgium, 2ULB/Erasmus Hospital, Neurology, Brussels," exact="Belgium" post="Background: Patient satisfaction with a chronic treatment may affect"/>
  <result pre="Barcelona, Spain, 2Hospital Universitari Germans Trias i Pujol, Pharmacy, Barcelona," exact="Spain" post="Background: Natalizumab is an effective treatment for multiple sclerosis"/>
  <result pre="A Ascherio 1 1Harvard School of Public Health, Boston, MA," exact="United States," post="2University Hospital of Turku, Turku, Finland, 3National Institute for"/>
  <result pre="Turku, Turku, Finland, 3National Institute for Health and Welfare, Oulu," exact="Finland" post="Background: Adequate vitamin D nutrition is associated with a"/>
  <result pre="3Harvard School of Public Health, Department of Nutrition, Boston, MA," exact="United States," post="4Haukeland University Hospital, The Norwegian Multiple Sclerosis Competence Centre,"/>
  <result pre="11Research Institute of the McGill University Health Centre, Montréal, QC," exact="Canada" post="Background: A low vitamin D level has been associated"/>
  <result pre="1 1Tehran University of Medical Sciences, Department of Neurology, Tehran," exact="Iran, Islamic Republic of," post="2Kurdistan University of Medical Sciences, Kurdistan Environmental Health Research"/>
  <result pre="University of Medical Sciences, Kurdistan Environmental Health Research Center, Sanandaj," exact="Iran, Islamic Republic of," post="3Tehran University, Lab of Systems Biology and Bioinformatics (LBB),"/>
  <result pre="and Bioinformatics (LBB), Institute of Biochemistry and Biophysics (IBB), Tehran," exact="Iran, Islamic Republic of," post="4Tehran University of Medical Sciences, Center for Air Pollution"/>
  <result pre="Air Pollution Research (CAPR), Institute for Environmental Research (IER), Tehran," exact="Iran, Islamic Republic of" post="Background: Multiple Sclerosis (MS) incidence has dramatically increased in"/>
  <result pre="1Cardiff University, Institute for Psychological Medicine and Clinical Neuroscience, Cardiff," exact="United Kingdom," post="2University Hospital of Wales, Neurology, Cardiff, United Kingdom Background:"/>
  <result pre="Neuroscience, Cardiff, United Kingdom, 2University Hospital of Wales, Neurology, Cardiff," exact="United Kingdom" post="Background: There is evidence that presentation of multiple sclerosis"/>
  <result pre="3, M Fereidan-Esfahani 1 1Isfahan University of Medical Science, Isfahan," exact="Iran, Islamic Republic of," post="2Isfahan Research Commitee of Multiple Sclerosis, Isfahan, Iran, Islamic"/>
  <result pre="Islamic Republic of, 2Isfahan Research Commitee of Multiple Sclerosis, Isfahan," exact="Iran, Islamic Republic of," post="3Tarbiat Modares University, Tehran, Iran, Islamic Republic of Background:"/>
  <result pre="Sclerosis, Isfahan, Iran, Islamic Republic of, 3Tarbiat Modares University, Tehran," exact="Iran, Islamic Republic of" post="Background: The steep rising in the number of multiple"/>
  <result pre="Sassari, Italy, 6McGill University Health Centre Research Institute, Montreal, QC," exact="Canada" post="Background: Early life sun exposure has been shown to"/>
  <result pre="study that enrolled MS cases and population-based controls in Canada," exact="Italy" post="and Norway. 564 cases and 939 controls enrolled in"/>
  <result pre="enrolled in Canada, 650 cases and 1232 controls enrolled in" exact="Italy" post="and 911 cases and 1628 controls enrolled in Norway,"/>
  <result pre="Queensland Centre for Mental Health Research, Queensland Brain Institute, Brisbane," exact="Australia" post="Background: Vitamin D status at birth may be associated"/>
  <result pre="multiple sclerosis. Methods: This was a population-based case-control study in" exact="Sweden" post="including 459 incident cases of multiple sclerosis and 663"/>
  <result pre="of MS. P337 Multiple sclerosis in Møre and Romsdal, Western" exact="Norway" post="1960-2013. Time trends of incidence and prevalence through more"/>
  <result pre="Clinical Research, Department of Cancer Research and Molecular Medicine, Trondheim," exact="Norway" post="Background: A recent Norwegian study shows an increasing prevalence"/>
  <result pre="of Alberta, Edmonton, AB, Canada, 6University of Calgary, Calgary, AB," exact="Canada" post="Background: British Columbia (BC) is the most western province"/>
  <result pre="Svenson 1, D Schopflocher 1 1University of Alberta, Edmonton, AB," exact="Canada" post="Background: In the past persons with multiple sclerosis (MS)"/>
  <result pre="study’s goal was to describe mortality due to MS in" exact="Canada" post="from 1975 to 2009 by age and gender and"/>
  <result pre="Melbourne, Melbourne Brain Centre, Parkville, Australia, 2Craigavon Area Hospital, Portadown," exact="United Kingdom," post="3University of Bari, Department of Basic Medical Sciences, Neuroscience"/>
  <result pre="Sydney, Australia, 16Neuro Rive-Sud, Hôpital Charles LeMoyne, Greenfield Park, QC," exact="Canada" post="Background: Previous studies into seasonal variation of relapses in"/>
  <result pre="Neurology, Oslo, Norway, 2University Of Oslo, Faculty of Medicine, Oslo," exact="Norway" post="Background: Several studies have shown an increased risk of"/>
  <result pre="1Brigham and Women’s Hospital, Neurology, Partners MS Center, Brookline, MA," exact="United States," post="2EMD Serono, Inc., Rockland, MA, United States Background: Several"/>
  <result pre="Center, Brookline, MA, United States, 2EMD Serono, Inc., Rockland, MA," exact="United States" post="Background: Several recent studies have described a decreasing relapse"/>
  <result pre="of MS hypothesis. P343 The incidence of multiple sclerosis in" exact="New Zealand," post="2013: a population- based study S Alla 1,2, J"/>
  <result pre="D Mason 2,5 1University of Otago, School of Medicine, Christchurch," exact="New Zealand," post="2New Zealand Brain Research Institute, Christchurch, New Zealand, 3University"/>
  <result pre="Medicine, Christchurch, New Zealand, 2New Zealand Brain Research Institute, Christchurch," exact="New Zealand," post="3University of Otago, Deans Department, Christchurch, New Zealand, 4University"/>
  <result pre="Institute, Christchurch, New Zealand, 3University of Otago, Deans Department, Christchurch," exact="New Zealand," post="4University of Canterbury, Public Health, Christchurch, New Zealand, 5Christchurch"/>
  <result pre="Department, Christchurch, New Zealand, 4University of Canterbury, Public Health, Christchurch," exact="New Zealand," post="5Christchurch Public Hospital, Department of Neurology, Christchurch, New Zealand"/>
  <result pre="Christchurch, New Zealand, 5Christchurch Public Hospital, Department of Neurology, Christchurch," exact="New Zealand" post="Background: Worldwide, the incidence of multiple sclerosis (MS) appears"/>
  <result pre="are no national estimates of the incidence of MS in" exact="New Zealand" post="(NZ). Objectives: The aim of this study is to"/>
  <result pre="2013 and examine its relationship with the latitudinal gradient in" exact="New Zealand" post="(35- 48 0S). Methods: The data were obtained from"/>
  <result pre="Program in Translational NeuroPsychiatric Genomics, Department of Neurology, Boston, MA," exact="United States," post="2Harvard Medical School, Boston, MA, United States, 3National Institute"/>
  <result pre="Neurology, Boston, MA, United States, 2Harvard Medical School, Boston, MA," exact="United States," post="3National Institute of Neurological Disorders and Stroke, Translational Neuroradiology"/>
  <result pre="Disorders and Stroke, Translational Neuroradiology Unit, Neuroimmunology Branch, Bethesda, MD," exact="United States" post="Background: There is currently no reliable tool to guide"/>
  <result pre="study that has recruited over 2,500 subjects from across the" exact="United States" post="since 2011. Subjects with FDR and self-diagnosis of MS"/>
  <result pre="Italy, 9State University of Medicine and Pharmacy ‘Nicolae Testemitanu’, Chisinau," exact="Moldova, Republic of," post="10Hospital Universitari Josep Trueta, Neurologia, Girona, Spain, 11Hospital Santa"/>
  <result pre="Neurology Dept., Figueres, Spain, 13European Multiple Sclerosis Platform, EMSP, Brussels," exact="Belgium" post="Background: The attempt to define the burden of MS"/>
  <result pre="of 18 databases contacted, EPI-Q was successfully administered to Croatia," exact="Czech Republic," post="Denmark, Finland, Germany, Italy (Liguria, Tuscany, iMED), Norway, Poland,"/>
  <result pre="was successfully administered to Croatia, Czech Republic, Denmark, Finland, Germany," exact="Italy" post="(Liguria, Tuscany, iMED), Norway, Poland, Serbia, Spain, Sweden and"/>
  <result pre="Finland, Germany, Italy (Liguria, Tuscany, iMED), Norway, Poland, Serbia, Spain," exact="Sweden" post="and United Kingdom. Population-based epidemiological data collected since 2003"/>
  <result pre="Italy (Liguria, Tuscany, iMED), Norway, Poland, Serbia, Spain, Sweden and" exact="United Kingdom." post="Population-based epidemiological data collected since 2003 can be integrated"/>
  <result pre="of 18,000,000 for sub-areas in Catalunya/Spain, Italy, Sweden, UK, Norway," exact="Finland" post="and Serbia, despite some heterogeneity across regions. Conclusions: Benefitting"/>
  <result pre="1 1Copenhagen University Hospital Rigshospitalet, Danish Multiple Sclerosis Center, Copenhagen," exact="Denmark" post="Background: Vitamin D insufficiency is common among multiple sclerosis"/>
  <result pre="San Raffaele, Laboratory of Genetics of Neurological Complex Disorders, Milan," exact="Italy" post="Background: Multiple sclerosis (MS) is a multifactorial neurologic disease"/>
  <result pre="Waubant 1 1UCSF Regional Pediatric MS Center, San Francisco, CA," exact="United States," post="2University of Pennsylvania, Department of Neurology, Philadelphia, PA, United"/>
  <result pre="United States, 2University of Pennsylvania, Department of Neurology, Philadelphia, PA," exact="United States," post="3SUNY Stony Brook, Department of Neurology, Stony Brook, NY,"/>
  <result pre="States, 3SUNY Stony Brook, Department of Neurology, Stony Brook, NY," exact="United States," post="4UT Southwestern, Department of Neurology, Dallas, TX, United States,"/>
  <result pre="NY, United States, 4UT Southwestern, Department of Neurology, Dallas, TX," exact="United States," post="5SUNY Buffalo, The Pediatric MS Center at the Jacobs"/>
  <result pre="Pediatric MS Center at the Jacobs Neurological Institute, Buffalo, NY," exact="United States," post="6Loma Linda University, Department of Child Neurology, Loma Linda,"/>
  <result pre="6Loma Linda University, Department of Child Neurology, Loma Linda, CA," exact="United States," post="7Mayo Clinic, Department of Neurology, Rochester, MN, United States,"/>
  <result pre="CA, United States, 7Mayo Clinic, Department of Neurology, Rochester, MN," exact="United States," post="8Alabama Pediatric MS Center, Birmingham, AL, United States, 9Northwestern"/>
  <result pre="Rochester, MN, United States, 8Alabama Pediatric MS Center, Birmingham, AL," exact="United States," post="9Northwestern Feinberg School of Medicine, Department of Neurology, Chicago,"/>
  <result pre="9Northwestern Feinberg School of Medicine, Department of Neurology, Chicago, IL," exact="United States," post="10Massachusetts General Hospital, Partners Pediatric MS Center, Boston, MA,"/>
  <result pre="States, 10Massachusetts General Hospital, Partners Pediatric MS Center, Boston, MA," exact="United States," post="11University of Utah, Department of Pediatrics, Salt Lake City,"/>
  <result pre="11University of Utah, Department of Pediatrics, Salt Lake City, UT," exact="United States," post="12University of Utah, Department of Neurology, Salt Lake City,"/>
  <result pre="12University of Utah, Department of Neurology, Salt Lake City, UT," exact="United States" post="Background: Environmental and dietary factors have become increasingly recognized"/>
  <result pre="Norway, 2Norwegian MS Registry &amp;amp; Biobank, Department of Neurology, Bergen," exact="Norway" post="Background: Hordaland County, Western Norway is a high risk"/>
  <result pre="Biobank, Department of Neurology, Bergen, Norway Background: Hordaland County, Western" exact="Norway" post="is a high risk area for multiple sclerosis (MS)."/>
  <result pre="Brazil, 21Clinica de Curitiba, Curitiba, Brazil, 22INCA, Rio de Janeiro," exact="Brazil" post="Background: Although population-based studies have estimated that the NMO"/>
  <result pre="varied from 43% in Venezuela, 14% in Brazil, 8% in" exact="Paraguay" post="and 2% in Argentina and the frequency of NonWhites"/>
  <result pre="Venezuela, 14% in Brazil, 8% in Paraguay and 2% in" exact="Argentina" post="and the frequency of NonWhites in NMO was respectively"/>
  <result pre="for Neurologic Diseases - Brigham and Women’s Hospital, Boston, MA," exact="United States" post="Background: Sodium has been recently reported to promote the"/>
  <result pre="1 1Johns Hopkins University School of Medicine, Neurology, Baltimore, MD," exact="United States," post="2University of California San Francisco, San Francisco, CA, United"/>
  <result pre="United States, 2University of California San Francisco, San Francisco, CA," exact="United States," post="3University of California San Francisco, Neurology, San Francisco, CA,"/>
  <result pre="States, 3University of California San Francisco, Neurology, San Francisco, CA," exact="United States" post="Background: While vitamin D insufficiency is a risk factor"/>
  <result pre="Pugliatti 6 1State University of Medicine and Pharmacy ‘N.Testemiţanu’, Chisinau," exact="Moldova, Republic of," post="2Institute of Neurology and Neurosurgery, Dept. of Neurology, Chisinau,"/>
  <result pre="of, 2Institute of Neurology and Neurosurgery, Dept. of Neurology, Chisinau," exact="Moldova, Republic of," post="3Dept. of Clinical and Experimental Medicine, University of Sassari,"/>
  <result pre="University of Sassari, Sassari, Italy, 4District Hospital of Riscani, Riscani," exact="Moldova, Republic of," post="5Ospedale Maggiore della Carità, Novara, Italy, 6University of Sassari,"/>
  <result pre="6University of Sassari, Dept. of Clinical and Experimental Medicine, Sassari," exact="Italy" post="Background: In Europe the total prevalence of MS is"/>
  <result pre="Europe is scarce and out of date. Data from Bulgaria," exact="Czech Republic," post="Hungary, Poland, Romania, Russia, Russia, Slovakia, and Ukraine show"/>
  <result pre="Bulgaria, Czech Republic, Hungary, Poland, Romania, Russia, Russia, Slovakia, and" exact="Ukraine" post="show a prevalence of 21 to 83, and an"/>
  <result pre="evidence is rather consistent with what reported for neighboring countries" exact="Romania" post="and Ukraine. Acknowledgements: Ministry of Health, Republic of Moldova;"/>
  <result pre="de Buenos Aires, Buenos Aires, Argentina, 2Hospital Italiano, Buenos Aires," exact="Argentina" post="Background: Epidemiological studies in multiple sclerosis (MS) suggest a"/>
  <result pre="1,2,3 1Brigham and Women’s Hospital, Department of Neurology, Boston, MA," exact="United States," post="2Broad Institute, Program in Medical and Population Genetics, Cambridge,"/>
  <result pre="2Broad Institute, Program in Medical and Population Genetics, Cambridge, MA," exact="United States," post="3Harvard Medical School, Boston, MA, United States, 4San Raffaele"/>
  <result pre="Genetics, Cambridge, MA, United States, 3Harvard Medical School, Boston, MA," exact="United States," post="4San Raffaele Scientific Institute, Milan, Italy Background: Multiple sclerosis"/>
  <result pre="School, Boston, MA, United States, 4San Raffaele Scientific Institute, Milan," exact="Italy" post="Background: Multiple sclerosis (MS) is a demyelinating autoimmune disease"/>
  <result pre="Institute, Aarhus, Denmark, 7Rigshospitalet, The Danish Multiple Sclerosis Registry, Copenhagen," exact="Denmark" post="Background: Animal studies have suggested that drugs that inhibit"/>
  <result pre="Arroyo 1, R Alvarez-Lafuente 1 1Hospital Clinico San Carlos, Madrid," exact="Spain" post="Background: Systemic or locally produced 1,25(OH)(2) Vitamin D3 exerts"/>
  <result pre="1, M Etemadifar 1 1Isfahan University of Medical Science, Isfahan," exact="Iran, Islamic Republic of" post="Background: It is estimated that early onset MS (EOMS)"/>
  <result pre="Herbert 1 1NYU School of Medicine, Neurology, New York, NY," exact="United States," post="2University of Alabama at Birmingham, Epidemiology, Birmingham, AL, United"/>
  <result pre="United States, 2University of Alabama at Birmingham, Epidemiology, Birmingham, AL," exact="United States" post="Background: Patient-Derived Multiple Sclerosis Severity Score (P-MSSS) represents disease"/>
  <result pre="Paris, France, 5AP-HP - Salpetriere Hospital, Infectious Diseases Department, Paris," exact="France" post="Background: Age at onset of multiple sclerosis (MS) is"/>
  <result pre="at disease onset in familial and sporadic multiple sclerosis in" exact="Argentina" post="JI Rojas 1, L Patrucco 1, J Miguez 1,"/>
  <result pre="Carlos G Durand, Buenos Aires, Argentina, 9Hospital Aleman, Buenos Aires," exact="Argentina" post="Background: Anticipation of age at onset in younger generations"/>
  <result pre="1 1University of Edinburgh, Center for Population Health Sciences, Edinburgh," exact="United Kingdom" post="Background: Vitamin D deficiency has been associated with several"/>
  <result pre="clinical characteristics of multiple sclerosis in the city of Tlemcen," exact="Algeria" post="Z Barka Bedrane 1, L Henaoui 2, M Senoussaoui"/>
  <result pre="d’Epidemiologie, Tlemcen, Algeria, 3CHU Frantz Fanon, Service de Neurologie, Blida," exact="Algeria" post="Background: Previous epidemiological studies have indicated that Algeria is"/>
  <result pre="Neurologie, Blida, Algeria Background: Previous epidemiological studies have indicated that" exact="Algeria" post="is a low-risk zone for multiple sclerosis (MS). Objectives:"/>
  <result pre="Tlemcen city. Methods: Tlemcen is located in the northwest of" exact="Algeria" post="at 520 km from the capital Algiers and 64"/>
  <result pre="School of Medicine, Department of Neurology, Sendai, Japan, 2Biogen Idec" exact="Japan" post="Ltd, Tokyo, Japan Background: Epidemiological data on the disability"/>
  <result pre="Department of Neurology, Sendai, Japan, 2Biogen Idec Japan Ltd, Tokyo," exact="Japan" post="Background: Epidemiological data on the disability status and progression"/>
  <result pre="been well established. Kumar et al. reported that MS in" exact="Japan" post="was associated with less disability than UK based on"/>
  <result pre="Flanagan 1, OH Kantarci 1 1Mayo Clinic, Neurology, Rochester, MN," exact="United States" post="Background: Risk of developing multiple sclerosis (MS) has been"/>
  <result pre="Islam 3 1University of Southern California, Neurology, Los Angeles, CA," exact="United States," post="2UAW, Public Health, Dhaka, Bangladesh, 3University of Southern California,"/>
  <result pre="Bangladesh, 3University of Southern California, Preventive Medicine, Los Angeles, CA," exact="United States" post="Background: CNS inflammation and axonal degeneration contribute to multiple"/>
  <result pre="MD Goldman 2 1University of Virginia, Pediatric Neurology, Galloway, OH," exact="United States," post="2University of Virginia, Charlottesville, VA, United States Background: Identification"/>
  <result pre="Neurology, Galloway, OH, United States, 2University of Virginia, Charlottesville, VA," exact="United States" post="Background: Identification of modifiable risk factors for multiple sclerosis"/>
  <result pre="Hospital, Department of Medicine, Phitsanulok, Thailand, 3Bumrungrad International Hospital, Bangkok," exact="Thailand" post="Background: There had several studies demonstrated that low level"/>
  <result pre="Thai patients with IIDCDs attending the MS Clinic, Siriraj Hospital," exact="Thailand" post="during April 2012 and January 2014. Correlations between Expanded"/>
  <result pre="1,2,3 1Jacobs Comprehensive MS Treatment and Research Center, Buffalo, NY," exact="United States," post="2New York State MS Consortium, Buffalo, NY, United States,"/>
  <result pre="NY, United States, 2New York State MS Consortium, Buffalo, NY," exact="United States," post="3SUNY University of Buffalo School of Medicine and Biomedical"/>
  <result pre="of Medicine and Biomedical Sciences, Department of Neurology, Buffalo, NY," exact="United States," post="4MS Center of Northeastern New York, Latham, NY, United"/>
  <result pre="United States, 4MS Center of Northeastern New York, Latham, NY," exact="United States," post="5SUNY-Stony Brook MS Comprehensive Care Center, Neurology, Stony Brook,"/>
  <result pre="5SUNY-Stony Brook MS Comprehensive Care Center, Neurology, Stony Brook, NY," exact="United States," post="6New York University Langone Medical Center, MS Comprehensive Care"/>
  <result pre="Langone Medical Center, MS Comprehensive Care Center, New York, NY," exact="United States," post="7University of Rochester Medical Center, Department Neurology, Rochester, NY,"/>
  <result pre="States, 7University of Rochester Medical Center, Department Neurology, Rochester, NY," exact="United States," post="8SUNY Upstate Medical University, Neurology, Rochester, NY, United States,"/>
  <result pre="NY, United States, 8SUNY Upstate Medical University, Neurology, Rochester, NY," exact="United States," post="9Winthrop University Hospital, Winthrop Comprehensive MS Care Center, Mineola,"/>
  <result pre="9Winthrop University Hospital, Winthrop Comprehensive MS Care Center, Mineola, NY," exact="United States," post="10Alpha Neurology, Staten Island University Hospital, Staten Island, NY,"/>
  <result pre="States, 10Alpha Neurology, Staten Island University Hospital, Staten Island, NY," exact="United States," post="11Albany Medical College, Neurology, Albany, NY, United States, 12Buffalo"/>
  <result pre="Island, NY, United States, 11Albany Medical College, Neurology, Albany, NY," exact="United States," post="12Buffalo Neuroimaging Analysis Center, Buffalo, NY, United States, 13SUNY"/>
  <result pre="Albany, NY, United States, 12Buffalo Neuroimaging Analysis Center, Buffalo, NY," exact="United States," post="13SUNY - Buffalo Pharmaceutical Sciences, Neuroscience, Buffalo, OK, United"/>
  <result pre="United States, 13SUNY - Buffalo Pharmaceutical Sciences, Neuroscience, Buffalo, OK," exact="United States" post="Background: Multiple sclerosis (MS) patients progress at varying rates"/>
  <result pre="Department, Montpellier, France, 5INSERM U 1051, Université Montpellier 1, Montpellier," exact="France" post="Background: Vitamin D deficiency is a recognized risk factor"/>
  <result pre="JL Frederiksen 1 1Glostrup Hospital, University of Copenhagen, Neurology, Glostrup," exact="Denmark" post="Background: The aetiology of multiple sclerosis (MS) is complex,"/>
  <result pre="LA Rolak 1, S Anderson 1 1Marshfield Clinic, Marshfield, WI," exact="United States" post="Background: The extent to which disability in MS arises"/>
  <result pre="1,3, TF Scott 1,3 1Allegheny General Hospital, Neurology, Pittsburgh, PA," exact="United States," post="2University of South Carolina, Columbia, SC, United States, 3Drexel"/>
  <result pre="Pittsburgh, PA, United States, 2University of South Carolina, Columbia, SC," exact="United States," post="3Drexel University College of Medicine, Pittsburgh, PA, United States"/>
  <result pre="SC, United States, 3Drexel University College of Medicine, Pittsburgh, PA," exact="United States" post="Background: Progression occurring with or without clinical relapses creates"/>
  <result pre="and Neurosurgery, Montréal, QC, Canada, 4Toronto University, Immunology, Toronto, ON," exact="Canada" post="Background: Multiple Sclerosis (MS) is classically considered as a"/>
  <result pre="H Wiendl 1 1University Hospital Münster, Department of Neurology, Münster," exact="Germany" post="Background: Transmigration of activated encephalitogenic T cells across the"/>
  <result pre="QC, Canada, 2Stony Brook School of Medicine, Stony Brook, NY," exact="United States," post="3Brigham &amp;amp; Women’s Hospital, Boston, MA, United States Background:"/>
  <result pre="Brook, NY, United States, 3Brigham &amp;amp; Women’s Hospital, Boston, MA," exact="United States" post="Background: Serine protease inhibitor clade E member 1 (Serpine1)"/>
  <result pre="Caen, Caen, France, 2University of Southern California, Los Angeles, CA," exact="United States," post="3University Hospital of Caen, Neurology, Caen, France Background: Today"/>
  <result pre="Angeles, CA, United States, 3University Hospital of Caen, Neurology, Caen," exact="France" post="Background: Today MR diagnosis and therapeutic assessment of multiple"/>
  <result pre="Inc., Neurology eTIP, Translational &amp;amp; Biomarker Research Group, Billerica, MA," exact="United States," post="2Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical"/>
  <result pre="Hospital, Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA," exact="United States" post="Background: ATX-MS-1467 (ATX), a mixture of 4 antigen-processing independent"/>
  <result pre="1, R Voskuhl 1 1University of California, Los Angeles, CA," exact="United States" post="Background: Chemokine (C-C motif) ligand 2 (CCL2), initially identified"/>
  <result pre="1, R Gold 1 1Ruhr-University Bochum, Department of Neurology, Bochum," exact="Germany" post="Background: Despite new insights into the genetics and epigenetics"/>
  <result pre="SS Zamvil 1 1University of California, Neurology, San Francsico, CA," exact="United States," post="2Stanford University, Pathology, Stanford, CA, United States Background: Laquinimod"/>
  <result pre="San Francsico, CA, United States, 2Stanford University, Pathology, Stanford, CA," exact="United States" post="Background: Laquinimod is a novel oral agent with immunomodulatory"/>
  <result pre="Immunology, Geneva, Switzerland, 2Geneva University Hospitals, Division of Neurology, Geneva," exact="Switzerland" post="Background: Serum oxysterols levels have been proposed as candidate"/>
  <result pre="Research, Graz, Austria, 3Karolinska Institute, Center for Molecular Medicine, Stockholm," exact="Sweden" post="Background: While cortical demyelinating lesions significantly contribute to disease"/>
  <result pre="Italy, 3Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Basel," exact="Switzerland" post="Background: Multiple sclerosis (MS) is an autoimmune disease affecting"/>
  <result pre="1, J Chun 1 1Scripps Research Institute, La Jolla, CA," exact="United States," post="2University of California San Diego, Neuroscience, La Jolla, CA,"/>
  <result pre="States, 2University of California San Diego, Neuroscience, La Jolla, CA," exact="United States" post="Background: Sphingosine 1-phosphate (S1P), a lysophospholipid, was shown to"/>
  <result pre="2Tohoku University Graduate School of Medicine, Department of Neurology, Sendai," exact="Japan" post="Background: Neuromyelitis optica (NMO) is an autoimmune disease associated"/>
  <result pre="Sinai, Corinne Goldsmith Dickinson Center for MS, New York, NY," exact="United States," post="2Icahn School of Medicine at Mount Sinai, Friedman Brain"/>
  <result pre="Medicine at Mount Sinai, Friedman Brain Institute, New York, NY," exact="United States," post="3Icahn School of Medicine at Mount Sinai, Neurology, New"/>
  <result pre="School of Medicine at Mount Sinai, Neurology, New York, NY," exact="United States," post="4John Radcliffe Hospital, Neuroimmunology Group, Oxford, United Kingdom, 5Teva"/>
  <result pre="York, NY, United States, 4John Radcliffe Hospital, Neuroimmunology Group, Oxford," exact="United Kingdom," post="5Teva Pharmaceuticals, Netanya, Israel, 6Johns Hopkins Hospital, Neurology, Baltimore,"/>
  <result pre="5Teva Pharmaceuticals, Netanya, Israel, 6Johns Hopkins Hospital, Neurology, Baltimore, MD," exact="United States" post="Background: Neuromyelitis optica (NMO) is an autoimmune neurologic disease"/>
  <result pre="Siders 1 1Neuroimmunology Research, Genzyme, a Sanofi Company, Framingham, MA," exact="United States" post="Background: Alemtuzumab is a humanized monoclonal antibody that selectively"/>
  <result pre="1 1University of California, Department of Neurology, Los Angeles, CA," exact="United States" post="Background: Gray matter atrophy is an important correlate to"/>
  <result pre="of Medicine, Biochemistry, Nagoya, Japan, 3Kobe Pharmaceutical University, Biochemistry, Kobe," exact="Japan" post="Background: Chondroitin sulfate proteoglycans (CSPGs) are the main component"/>
  <result pre="Esen 1, P Dore-Duffy 1 1Wayne State University, Detroit, MI," exact="United States" post="Background: Infiltration of immune cells into the CNS in"/>
  <result pre="1 1University of California, Department of Neurology, Los Angeles, CA," exact="United States" post="Background: Gray matter atrophy in cerebral cortex by magnetic"/>
  <result pre="TK Makar 1,2 1University of Maryland Baltimore, Neurology, Baltimore, MD," exact="United States," post="2MS Center of Excellence-EAST, VA Maryland Health Care System,"/>
  <result pre="Center of Excellence-EAST, VA Maryland Health Care System, Baltimore, MD," exact="United States" post="Background: Glatiramer acetate (GA) is one of the disease"/>
  <result pre="2 1University of Texas at San Antonio, San Antonio, TX," exact="United States," post="2University of Texas at San Antonio, Biology, San Antonio,"/>
  <result pre="2University of Texas at San Antonio, Biology, San Antonio, TX," exact="United States" post="Background: Macrophage migration inhibitory factor (MIF) is a proinflammatory"/>
  <result pre="1University of British Columbia, Pathology and Laboratory Medicine, Vancouver, BC," exact="Canada" post="Background: Multiple sclerosis (MS) is a complex inflammatory neurodegenerative"/>
  <result pre="Davis 1 1High Point Pharmaceuticals, LLC, Biology, High Point, NC," exact="United States," post="2High Point Pharmaceuticals, LLC, Chemistry, High Point, NC, United"/>
  <result pre="United States, 2High Point Pharmaceuticals, LLC, Chemistry, High Point, NC," exact="United States" post="Background: Pharmacological activation of nuclear factor (erythroid-derived 2)-like 2"/>
  <result pre="School of Medicine at Dartmouth, Department of Microbiology/Immunology, Hanover, NH," exact="United States" post="Background: The gut associated lymphoid tissue comprises 80% of"/>
  <result pre="1 1EMD Serono Research &amp;amp; Development Institute, Inc., Billerica, MA," exact="United States" post="Background: Plovamer acetate (PA) is a copolymer mixture of"/>
  <result pre="Barcelona, Spain, 2Hospital Universitari Germans Trias i Pujol, Neurosciences, Barcelona," exact="Spain" post="Background: Treatment with tolerogenic dendritic cells (TolDCs) loaded with"/>
  <result pre="of Medicine at University of California, Neurosurgery, Los Angeles, CA," exact="United States," post="2School of Medicine at University of California, Los Angeles,"/>
  <result pre="2School of Medicine at University of California, Los Angeles, CA," exact="United States," post="3School of Medicine at University of California at Riverside,"/>
  <result pre="of Medicine at University of California at Riverside, Riverside, CA," exact="United States" post="Background: Unlike autoimmune demyelinating pathology in multiple sclerosis (MS)"/>
  <result pre="Hospital San Raffaele, Neurology and INSPE-Institute of Experimental Neurology, Milan," exact="Italy" post="Background: Experimental Autoimmune Encephalomyelitis (EAE) is a pre-clinical disease"/>
  <result pre="1, LP Shriver 1,3 1University of Akron, Chemistry, Akron, OH," exact="United States," post="2Indiana University Northwest, Chemistry, Gary, IN, United States, 3University"/>
  <result pre="Akron, OH, United States, 2Indiana University Northwest, Chemistry, Gary, IN," exact="United States," post="3University of Akron, Biology, Akron, OH, United States Background:"/>
  <result pre="Gary, IN, United States, 3University of Akron, Biology, Akron, OH," exact="United States" post="Background: The copper chelator, cuprizone, has been used for"/>
  <result pre="Balgrist Hospital, Zurich, Switzerland, 3University Zurich, Brain Research Institute, Zurich," exact="Switzerland" post="Background: The targeted experimental autoimmune encephalomyelitis (EAE) model in"/>
  <result pre="University Hospital, Multiple Sclerosis Centre of Catalonia, Neuroimmunology Department, Barcelona," exact="Spain" post="Background: Semaphorin 7A (sema7A) is an immune semaphorin that"/>
  <result pre="1University of Illinois at Chicago, Neurology and Rehabilitation, Chicago, IL," exact="United States," post="2Columbia University, Psychiatry, New York, NY, United States Background:"/>
  <result pre="Chicago, IL, United States, 2Columbia University, Psychiatry, New York, NY," exact="United States" post="Background: The mechanisms that modulate disease severity and progression"/>
  <result pre="3Hospital Clinico Universitario, Valladolid, Spain, 4Hospital Clinico Universitario, Neurologia, Valladolid," exact="Spain" post="Background: Optic neuritis (ON) is a frequent and early"/>
  <result pre="Thessaloniki, Greece, 5Aristotle University of Thessaloniki, B’ Pathology Clinic, Thessaloniki," exact="Greece" post="Background: We recently describe evidence of epidemiological correlation between"/>
  <result pre="1 1Washington University in St. Louis, Neurology, St. Louis, MO," exact="United States," post="2Washington University in St. Louis, Developmental Biology, St. Louis,"/>
  <result pre="2Washington University in St. Louis, Developmental Biology, St. Louis, MO," exact="United States" post="Background: B cells are increasingly regarded as integral to"/>
  <result pre="University Hospital, Multiple Sclerosis Centre of Catalonia, Neuroimmunology Department, Barcelona," exact="Spain" post="Background: Previously we described that transferring bone marrow cells"/>
  <result pre="1Tisch MS Research Center of New York, New York, NY," exact="United States" post="Background: Transglutaminases (TGM) are a family of enzymes involved"/>
  <result pre="BEYOND Study Groups 1Harvard School of Public Health, Boston, MA," exact="United States," post="2Bayer Pharma AG, Berlin, Germany, 3University of Chicago Surgery"/>
  <result pre="Chicago Surgery Brain Research Institutes, Department of Neurology, Chicago, IL," exact="United States," post="4VU University Medical Center, Amsterdam, Netherlands, 5Università Vita-Salute San"/>
  <result pre="of New Jersey, Deptartment of Neurology and Neurosciences, Newark, NJ," exact="United States," post="7CHU-Hopital Pontchaillou, Rennes, France, 8Neuroimaging Research Unit, Division of"/>
  <result pre="Canada, 10University of California, Department of Neurology, San Francisco, CA," exact="United States," post="11Heinrich-Heine University, Department of Neurology, Düsseldorf, Germany, 12Wake Forest"/>
  <result pre="Düsseldorf, Germany, 12Wake Forest University School of Medicine, Winston-Salem, NC," exact="United States," post="13University Hospital Basel, Basel, Switzerland, 14UCL Institute of Neurology,"/>
  <result pre="13University Hospital Basel, Basel, Switzerland, 14UCL Institute of Neurology, London," exact="United Kingdom," post="15Hospital Universitari Vall d’Hebron, Barcelona, Spain, 16Division of Neurology,"/>
  <result pre="Institute of Psychiatry, Munich, Germany, 19Bayer HealthCare Pharmaceuticals, Whippany, NJ," exact="United States," post="20University Hospital of Bonn, Department of Neurology, Bonn, Germany"/>
  <result pre="United States, 20University Hospital of Bonn, Department of Neurology, Bonn," exact="Germany" post="Background: Genome wide association studies provide robust evidence that"/>
  <result pre="Genomics, Institute for the Neuroscience, Department of Neurology, Boston, MA," exact="United States," post="4Monash University, Monash Antibody Technologies Facility, Melbourne, Australia, 5Fred"/>
  <result pre="Facility, Melbourne, Australia, 5Fred Hutchinson Cancer Research Center, Seattle, WA," exact="United States," post="6Texas Biomedical Research Institute, Department of Genetics, San Antonio,"/>
  <result pre="6Texas Biomedical Research Institute, Department of Genetics, San Antonio, TX," exact="United States" post="Background: Epstein-Barr virus (EBV) is a ubiquitous double-stranded DNA"/>
  <result pre="Simão 1, EMV Reiche 1 1State University of Londrina, Londrina," exact="Brazil" post="Background: Studies showed that tumor necrosis factor beta ("/>
  <result pre="Life Labratory, Stockholm, Sweden, 4Karolinska Institutet, Department of Medicine, Stockholm," exact="Sweden" post="Background: The major genetic susceptibility factors for multiple sclerosis"/>
  <result pre="of Radiology, Bochum, Germany, 3Ruhr-University Bochum, Department of Neurology, Bochum," exact="Germany" post="Background: The genetic basis of multiple sclerosis (MS) as"/>
  <result pre="S Yoshimura 1, R Yamasaki 3, J-I Kira 1, The" exact="Japan" post="Multiple Sclerosis Genetics Consortium 1Neurological Institute, Graduate School of"/>
  <result pre="of Medical Sciences, Kyushu University, Department of Neurological Therapeutics, Fukuoka," exact="Japan" post="Background: Remarkable advances in genome technology, such as high-density"/>
  <result pre="patients, and 790 healthy individuals as a replication cohort in" exact="Japan" post="using high-density microarrays, containing 700 K probes corresponding to"/>
  <result pre="Neuroscience, Stockholm, Sweden, 2Karolinska Institutet, Institute of Environmental Medicine, Stockholm," exact="Sweden" post="Background: The sibling recurrence risk for multiple sclerosis (MS)"/>
  <result pre="1Erasmus MC, Neurology, Rotterdam, Netherlands, 2University Medical Centre Groningen, Groningen," exact="Netherlands" post="Background: In the recent IMSGC collaborative study 110 multiple"/>
  <result pre="S Baranzini 3, J Oksenberg 3, J-I Kira 1, the" exact="Japan" post="Multiple Sclerosis Genetics Consortium 1Kyushu University, Neurology, Fukuoka, Japan,"/>
  <result pre="Medicine, Fukuoka, Japan, 3University of California, Neurology, San Francisco, CA," exact="United States" post="Background: Multiple sclerosis (MS) is characterized by temporal and"/>
  <result pre="Civico Lugano, Lugano, Switzerland, 2Queen Mary University of London, London," exact="United Kingdom," post="3University of Oxford, Oxford, United Kingdom Background: Multiple sclerosis"/>
  <result pre="University of London, London, United Kingdom, 3University of Oxford, Oxford," exact="United Kingdom" post="Background: Multiple sclerosis (MS) is a complex disorder with"/>
  <result pre="1Brigham and Women’s Hospital, Center for Neurologic Diseases, Boston, MA," exact="United States," post="2Harvard Medical School, Boston, MA, United States, 3Brigham and"/>
  <result pre="Diseases, Boston, MA, United States, 2Harvard Medical School, Boston, MA," exact="United States," post="3Brigham and Women’s Hospital, Program in Translational NeuroPsychiatric Genomics,"/>
  <result pre="for the Neurosciences, Department of Neurology and Psychiatry, Boston, MA," exact="United States" post="Background: Multiple genetic as well as environmental factors influence"/>
  <result pre="1, S Simpson Jr 1 1Menzies Research Institute Tasmania, Hobart," exact="Australia" post="Background: Alterations in peripheral blood mononuclear cells (PBMC) production"/>
  <result pre="Italy, 3AOU Maggiore della Carità, MS Centre, SCDU Neurology, Novara," exact="Italy" post="Background: The mechanisms underlying the accumulation of neurological disability"/>
  <result pre="3 1Isfahan University of Medical Sciences, Molecular Biology Department, Isfahan," exact="Iran, Islamic Republic of," post="2Isfahan University of Medical Sciences, Isfahan MS and Neuroimmunology"/>
  <result pre="Sciences, Isfahan MS and Neuroimmunology Reseach Center, Immunology Department, Isfahan," exact="Iran, Islamic Republic of," post="3Isfahan University of Medical Sciences, Isfahan MS and Neuroimmunology"/>
  <result pre="Sciences, Isfahan MS and Neuroimmunology Reseach Center, Neurology Department, Isfahan," exact="Iran, Islamic Republic of" post="Background: Interleukin-1 (IL-1) family is a central mediator of"/>
  <result pre="DS Reich 1 1Translational Neuroradiology Unit, NINDS, NIH, Bethesda, MD," exact="United States," post="2Program in Translational NeuroPsychiatric Genomics, Departments of Neurology, Brigham"/>
  <result pre="Genomics, Departments of Neurology, Brigham and Women’s Hospital, Boston, MA," exact="United States," post="3Harvard Medical School, Boston, MA, United States, 4National Institute"/>
  <result pre="Hospital, Boston, MA, United States, 3Harvard Medical School, Boston, MA," exact="United States," post="4National Institute of Neurological Disorders and Stroke, NIH, Bethesda,"/>
  <result pre="4National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD," exact="United States" post="Background: Subclinical demyelinating lesions precede the onset of clinical"/>
  <result pre="della Carità, Novara, Italy, 6A. Avogadro University, Health Sciences, Novara," exact="Italy" post="Background: Several large international association studies identified over 100"/>
  <result pre="Guangzhou, China, 4Fifth Affiliated Hospital of Sun Yat-sen University, Guangzhou," exact="China" post="Background: Aquaporin 4 (AQP4) and anti-AQP4 autoantibodies（NMO-IgG） are involved"/>
  <result pre="S Gregory 1 1Duke Molecular Physiology Institute, Medicine, Durham, NC," exact="United States," post="2Duke University, Molecular Gnetics and Microbiology, Durham, NC, United"/>
  <result pre="United States, 2Duke University, Molecular Gnetics and Microbiology, Durham, NC," exact="United States," post="3Case Western Reserve University, Epidemiology and Biostatistics, Cleveland, OH,"/>
  <result pre="States, 3Case Western Reserve University, Epidemiology and Biostatistics, Cleveland, OH," exact="United States," post="4University of California, School of Public Health, Berkeley, CA,"/>
  <result pre="States, 4University of California, School of Public Health, Berkeley, CA," exact="United States," post="5Duke University Medical Center, Molecular Gnetics and Microbiology, Durham,"/>
  <result pre="5Duke University Medical Center, Molecular Gnetics and Microbiology, Durham, NC," exact="United States" post="Background: We previously established that rs6897932 in the interleukin"/>
  <result pre="Torino, Torino, Italy, 2IRCSS Ospedale Maggiore Policlinico di Milano, Milano," exact="Italy" post="Background: Progranulin (PGRN) is a multifunctional protein involved in"/>
  <result pre="6VU University Medical Center, Department of Epidemiology and Biostatistics, Amsterdam," exact="Netherlands" post="Background: White matter (WM) abnormalities and gray matter (GM)"/>
  <result pre="A Gajofatto 1, C Romualdi 8, MD Benedetti 1, S" exact="Monaco" post="1 1University Hospital of Verona, Dept. of Neurological and"/>
  <result pre="2Imperial College, Division of Brain Sciences, Faculty of Medicine, London," exact="United Kingdom," post="3Istituto Superiore di Sanità, Dept. of Cell Biology and"/>
  <result pre="of Information Engineering, Padova, Italy, 5Imperial College, Neuroscience Dept., London," exact="United Kingdom," post="6Swansea University, Institute of Life Science ‘ILS’, Swansea, United"/>
  <result pre="United Kingdom, 6Swansea University, Institute of Life Science ‘ILS’, Swansea," exact="United Kingdom," post="7Euganea Medica, Neuroradiology Unit, Padova, Italy, 8University of Padova,"/>
  <result pre="Unit, Padova, Italy, 8University of Padova, Dept. of Biology, Padova," exact="Italy" post="Background: Several studies suggested that grey matter (GM) atrophy"/>
  <result pre="E Caverzasi 1, J Gelfand 1, A Green 1,3, KM" exact="Jordan" post="1,4, W Stern 1, H-C von Büdingen 1, E"/>
  <result pre="Hauser 1, RG Henry 1,4,5 1UCSF, Neurology, San Francisco, CA," exact="United States," post="2University Hospital Basel, University of Basel, Neurology, Basel, Switzerland,"/>
  <result pre="of Basel, Neurology, Basel, Switzerland, 3UCSF, Opthalmology, San Francisco, CA," exact="United States," post="4Bioengineering Graduate Group, University of California San Francisco &amp;amp;"/>
  <result pre="California San Francisco &amp;amp; Berkeley, San Francisco &amp;amp; Berkeley, CA," exact="United States," post="5UCSF, Radiology and Biomedical Imaging, San Francisco, CA, United"/>
  <result pre="United States, 5UCSF, Radiology and Biomedical Imaging, San Francisco, CA," exact="United States" post="Background: In multiple sclerosis (MS) cerebral gray matter (GM)"/>
  <result pre="Sweden, 2Umeå University, Dept. of Radiation Sciences, Diagnostic Radiology, Umeå," exact="Sweden" post="Background: Brain atrophy is of great interest in many"/>
  <result pre="Evangelou 1 1University of Nottingham, Division of Clinical Neurosciences, Nottingham," exact="United Kingdom," post="2University of Nottingham, Sir Peter Mansfield MR Centre, Nottingham,"/>
  <result pre="Kingdom, 2University of Nottingham, Sir Peter Mansfield MR Centre, Nottingham," exact="United Kingdom," post="3Queen Elizabeth Hospital, London, United Kingdom, 4University of Nottingham,"/>
  <result pre="Mansfield MR Centre, Nottingham, United Kingdom, 3Queen Elizabeth Hospital, London," exact="United Kingdom," post="4University of Nottingham, School of Psychology, Nottingham, United Kingdom"/>
  <result pre="London, United Kingdom, 4University of Nottingham, School of Psychology, Nottingham," exact="United Kingdom" post="Background: Focal cortical demyelination occurs in all MS phenotypes"/>
  <result pre="of Neurology, NMR Research Unit, Queen Square MS Center, London," exact="United Kingdom," post="2University of Genoa, Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics,"/>
  <result pre="of Neurology, Basel, Switzerland, 4Cardiff University, Department of Psychology, Cardiff," exact="United Kingdom," post="5Xuanwu Hospital of Capital Medical University, Beijing, China, 6National"/>
  <result pre="(NIHR) University College London Hospitals (UCLH) Biomedical Research Centre, London," exact="United Kingdom" post="Background: While motor function depends on the integration of"/>
  <result pre="Mainero 1,2 1AA Martinos Center for Biomedical Imaging, Charlestown, MA," exact="United States," post="2Harvard University, Boston, MA, United States, 3Ecole Polytechnique de"/>
  <result pre="Biomedical Imaging, Charlestown, MA, United States, 2Harvard University, Boston, MA," exact="United States," post="3Ecole Polytechnique de Montréal, Montreal, QC, Canada, 4Beth Israel"/>
  <result pre="United States, 3Ecole Polytechnique de Montréal, Montreal, QC, Canada, 4Beth" exact="Israel" post="Deaconess Medical Center, Boston, MA, United States Background: Subpial"/>
  <result pre="Montreal, QC, Canada, 4Beth Israel Deaconess Medical Center, Boston, MA," exact="United States" post="Background: Subpial and diffuse white matter (WM) injury are"/>
  <result pre="Goettingen, Germany, 8Siemens Schweiz AG, Healthcare Sector IM&amp;amp;WS S, Renens," exact="Switzerland" post="Background: Multiple sclerosis (MS) is a disease with heterogeneous"/>
  <result pre="Department of Radiology, Division of Diagnostic and Interventional Neuroradiology, Basel," exact="Switzerland" post="Background: Multiple Sclerosis (MS) is traditionally considered a white"/>
  <result pre="Medical Center, Amsterdam, Netherlands, 3Cleveland Clinic, Neurological Institute, Cleveland, OH," exact="United States," post="4Novartis Pharma AG, Basel, Switzerland, 5Novartis Pharmaceuticals Corporation, East"/>
  <result pre="Pharma AG, Basel, Switzerland, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ," exact="United States," post="6University Hospital, Department of Neurology, Basel, Switzerland Background: Brain"/>
  <result pre="Hanover, NJ, United States, 6University Hospital, Department of Neurology, Basel," exact="Switzerland" post="Background: Brain volume loss (BVL) in multiple sclerosis (MS)"/>
  <result pre="Y Wang 1,2, D Pitt 4 1Cornell University, Ithaca, NY," exact="United States," post="2Weill Medical College, New York, NY, United States, 3Yale"/>
  <result pre="Ithaca, NY, United States, 2Weill Medical College, New York, NY," exact="United States," post="3Yale University, New Haven, CT, United States, 4Yale University,"/>
  <result pre="New York, NY, United States, 3Yale University, New Haven, CT," exact="United States," post="4Yale University, New Haven, NY, United States Background: A"/>
  <result pre="New Haven, CT, United States, 4Yale University, New Haven, NY," exact="United States" post="Background: A key feature of inflamed multiple sclerosis lesions"/>
  <result pre="M Castellaro 3, A Morra 4, F Bortolon 5, S" exact="Monaco" post="1, P Manganotti 1 1University Hospital of Verona, Dept."/>
  <result pre="Neuroradiology Unit, Padova, Italy, 5Multiple Sclerosis Centre, ULSS 6, Vicenza," exact="Italy" post="Background: Epilepsy occurs more frequently in Multiple Sclerosis (MS)"/>
  <result pre="C Crainiceanu 1 1Johns Hopkins, Department of Biostatistics, Baltimore, MD," exact="United States," post="2University of Pennsylvania, Department of Biostatistics and Epidemiology, Philadelphia,"/>
  <result pre="2University of Pennsylvania, Department of Biostatistics and Epidemiology, Philadelphia, PA," exact="United States," post="3Johns Hopkins, Institute of Genetic Medicine, Baltimore, MD, United"/>
  <result pre="United States, 3Johns Hopkins, Institute of Genetic Medicine, Baltimore, MD," exact="United States," post="4National Institute of Neurological Disorders and Stroke, Translational Neuroradiology"/>
  <result pre="of Neurological Disorders and Stroke, Translational Neuroradiology Unit, Bethesda, MD," exact="United States" post="Background: Magnetic resonance imaging (MRI) can be used to"/>
  <result pre="4University of British Columbia, Pathology and Laboratory Medicine, Vancouver, BC," exact="Canada" post="Background: Focal lesions generally accumulate over time in the"/>
  <result pre="Gallo 1 1University of Padova, Department of Neuroscience SNPSRR, Padova," exact="Italy" post="Background: Cortical lesions can be observed at multiple sclerosis"/>
  <result pre="2 1Turku University Hospital, Turku, Finland, 2Turku PET Centre, Turku," exact="Finland" post="Background: In secondary progressive multiple sclerosis (SPMS),there is diffuse"/>
  <result pre="Klawiter 3 1Massachusetts General Hospital, Department of Radiology, Boston, MA," exact="United States," post="2Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical"/>
  <result pre="Martinos Center for Biomedical Imaging, Department of Radiology, Boston, MA," exact="United States," post="3Massachusetts General Hospital, Department of Neurology, Boston, MA, United"/>
  <result pre="United States, 3Massachusetts General Hospital, Department of Neurology, Boston, MA," exact="United States," post="4Stanford University, Richard M. Lucas Center for Imaging, Department"/>
  <result pre="M. Lucas Center for Imaging, Department of Radiology, Stanford, CA," exact="United States" post="Background: Axonal damage is considered the pathologic substrate of"/>
  <result pre="Uitdehaag 1, A Petzold 1 1VU University Medical Centre, Amsterdam," exact="Netherlands" post="Background: In order to investigate the dynamics of neuroaxonal"/>
  <result pre="Institute, Montreal, QC, Canada, 6Children’s Hospital of Philadelphia, Philadelphia, PA," exact="United States" post="Background: Functional connectivity between brain regions may be disrupted"/>
  <result pre="Netherlands, 4VU University Medical Center, Physics &amp;amp; Medical Technology, Amsterdam," exact="Netherlands" post="Background: Multiple sclerosis (MS) is characterized by progressive white"/>
  <result pre="Amsterdam, Netherlands, 4VU University Medical Center, Dept of Neurology, Amsterdam," exact="Netherlands" post="Background: Gray matter (GM) atrophy is common in multiple"/>
  <result pre="B Rypma 1,2 1University of Texas at Dallas, Dallas, TX," exact="United States," post="2University of Texas Southwestern Medical Center, Dallas, TX, United"/>
  <result pre="United States, 2University of Texas Southwestern Medical Center, Dallas, TX," exact="United States" post="Background: Multiple Sclerosis (MS) is characterized by a high"/>
  <result pre="1 1Massachusetts General Hospital, Harvard Medical School, Neurology, Boston, MA," exact="United States," post="2Massachusetts General Hospital, Harvard Medical School, Psychiatry, Boston, MA,"/>
  <result pre="States, 2Massachusetts General Hospital, Harvard Medical School, Psychiatry, Boston, MA," exact="United States," post="3Massachusetts General Hospital, Harvard Medical School, Radiology, Boston, MA,"/>
  <result pre="States, 3Massachusetts General Hospital, Harvard Medical School, Radiology, Boston, MA," exact="United States" post="Background: When used in conjunction with resting state functional"/>
  <result pre="of Colorado School of Medicine, Department of Neurology, Aurora, CO," exact="United States," post="2Analysis Group, Inc., Boston, MA, United States, 3Novartis Pharmaceuticals"/>
  <result pre="Neurology, Aurora, CO, United States, 2Analysis Group, Inc., Boston, MA," exact="United States," post="3Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States Background:"/>
  <result pre="Boston, MA, United States, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ," exact="United States" post="Background: Multiple sclerosis (MS) has been associated with progressive"/>
  <result pre="Hospital and Intermountain Health Care, Radiology, Salt Lake City, UT," exact="United States," post="2Rocky Mountain MS Research Group, Salt Lake City, UT,"/>
  <result pre="States, 2Rocky Mountain MS Research Group, Salt Lake City, UT," exact="United States" post="Background: The greater efficacy of Natalizumab (NAB) in the"/>
  <result pre="Pitiot 5 1University of Nottingham, Division of Clinical Neurosciences, Nottingham," exact="United Kingdom," post="2University of Nottingham, Sir Peter Mansfield MR Centre, Nottingham,"/>
  <result pre="Kingdom, 2University of Nottingham, Sir Peter Mansfield MR Centre, Nottingham," exact="United Kingdom," post="3Leicester Royal Infirmary, Leicester, United Kingdom, 4University of Nottingham,"/>
  <result pre="Mansfield MR Centre, Nottingham, United Kingdom, 3Leicester Royal Infirmary, Leicester," exact="United Kingdom," post="4University of Nottingham, Nottingham, United Kingdom, 5University of Nottingham,"/>
  <result pre="3Leicester Royal Infirmary, Leicester, United Kingdom, 4University of Nottingham, Nottingham," exact="United Kingdom," post="5University of Nottingham, School of Psychology, Nottingham, United Kingdom"/>
  <result pre="Nottingham, United Kingdom, 5University of Nottingham, School of Psychology, Nottingham," exact="United Kingdom" post="Background: Disability in MS patients has been correlated to"/>
  <result pre="Enzinger 1, F Fazekas 1 1Medical University of Graz, Graz," exact="Austria" post="Background: Increased iron concentration in cerebral deep grey matter"/>
  <result pre="and Multiple Sclerosis Research Section (nims), Department of Neurology, Zurich," exact="Switzerland" post="Background: Brain atrophy occurs early and in different subtypes"/>
  <result pre="University Hospital, Multiple Sclerosis Centre of Catalonia, Neuroimmunology Dept., Barcelona," exact="Spain" post="Background: 3-D magnetization prepared rapid gradient echo (MPRAGE) sequences"/>
  <result pre="Netherlands, 5VU University Medical Center, Physics and Medical Technology, Amsterdam," exact="Netherlands" post="Background: The relevance of grey matter (GM) pathology in"/>
  <result pre="Center, Radiology, Amsterdam, Netherlands, 3VU University Medical Center, Neurology, Amsterdam," exact="Netherlands" post="Background: Cognitive impairment is prominent in multiple sclerosis (MS)"/>
  <result pre="of Neurology, UCL, Department of Brain Repair and Rehabilitation, London," exact="United Kingdom," post="5University of Siena, Dept. of Medicine, Surgery &amp;amp; Neuroscience,"/>
  <result pre="Graz, Austria, 7Second University of Naples, Department of Neurology, Naples," exact="Italy" post="Background: Previous single center studies have shown an association"/>
  <result pre="of Neurology, School of Medicine and Biomedical Sciences, Buffalo, NY," exact="United States," post="3VU University Medical Center, Radiology, Amsterdam, Netherlands, 4University at"/>
  <result pre="of Neurology, School of Medicine and Biomedical Sciences, Buffalo, NY," exact="United States," post="5Don Gnocchi Foundation, IRCCS, Milan, Italy, 6MRI Clinical Translational"/>
  <result pre="Research Center, School of Medicine and Biomedical Sciences, Buffalo, NY," exact="United States" post="Background: Thalamic pathology is frequently found in multiple sclerosis"/>
  <result pre="Hangzhou, China, 2Xuanwu Hospital, Beijing, China, 3VU Medical Center, Amsterdam," exact="Netherlands" post="Background: The thalamus, a key node of the deep"/>
  <result pre="Center, Neurology, Amsterdam, Netherlands, 3VU University Medical Center, Radiology, Amsterdam," exact="Netherlands" post="Background: Memory deficits develop in 40-65% of the patients"/>
  <result pre="ON, Canada, 2Wayne State University, MR Research Facility, Detroit, MI," exact="United States," post="3Royal Victoria Regional Health Center, Barrie, ON, Canada, 4MRI"/>
  <result pre="Barrie, ON, Canada, 4MRI Institute of Biomedical Research, Detroit, MI," exact="United States" post="Background: Whole brain grey matter (GM) and white matter"/>
  <result pre="Universite, Marseille, France, 2Computer Assisted Clinical Medicine, Heidelberg University, Mannheim," exact="Germany" post="Background: Brain sodium MRI is an emerging tool that"/>
  <result pre="2Vall Hebron University Hospital, Magnetic Resonance Unit, Neuroradiology Department, Barcelona," exact="Spain" post="Background: Grey matter pathology is known to occur in"/>
  <result pre="of Philadelphia, University of Pennsylvania, Division of Neurology, Philadelphia, PA," exact="United States" post="Background: In contrast to the multifocal nature of multiple"/>
  <result pre="M Calabrese 1, I Mazzonetto 2, M Castellaro 2, S" exact="Monaco" post="1, A Bertoldo 2 1University of Verona, Department of"/>
  <result pre="Verona, Italy, 2University of Padova, Department of Information Engineering, Padova," exact="Italy" post="Background: Differences in the functional connectivity were vastly reported"/>
  <result pre="British Columbia, Vancouver, BC, Canada, 2EMD Serono, Inc., Rockland, MA," exact="United States," post="3University Hospital Basel, Basel, Switzerland Background: Chronic black holes"/>
  <result pre="Serono, Inc., Rockland, MA, United States, 3University Hospital Basel, Basel," exact="Switzerland" post="Background: Chronic black holes (CBHs) indicate irreversible axonal loss"/>
  <result pre="1,3,6 1Mount Sinai School of Medicine, Neurology, New York, NY," exact="United States," post="2Federico II University, Neuroscience, Naples, Italy, 3Mount Sinai School"/>
  <result pre="Italy, 3Mount Sinai School of Medicine, Radiology, New York, NY," exact="United States," post="4New York University, Radiology, New York, NY, United States,"/>
  <result pre="NY, United States, 4New York University, Radiology, New York, NY," exact="United States," post="5New York University, Neurology, New York, NY, United States,"/>
  <result pre="NY, United States, 5New York University, Neurology, New York, NY," exact="United States," post="6Mount Sinai School of Medicine, Neuroscience, New York, NY,"/>
  <result pre="States, 6Mount Sinai School of Medicine, Neuroscience, New York, NY," exact="United States" post="Background: Measurement of total sodium concentration (TSC) is useful"/>
  <result pre="Sclerosis Centre, Department of Neuroinflammation, UCL Institute of Neurology, London," exact="United Kingdom," post="2Xuanwu Hospital of Capital Medical University, Department of Neurology,"/>
  <result pre="(NIHR) University College London Hospitals (UCLH) Biomedical Research Centre, London," exact="United Kingdom" post="Background: In multiple sclerosis (MS), combined clinical and MRI"/>
  <result pre="British Columbia, Vancouver, BC, Canada, 2EMD Serono, Inc., Rockland, MA," exact="United States," post="3University Hospital Basel, Basel, Switzerland Background: Chronic black holes"/>
  <result pre="Serono, Inc., Rockland, MA, United States, 3University Hospital Basel, Basel," exact="Switzerland" post="Background: Chronic black holes (CBHs) represent irreversible axonal loss."/>
  <result pre="and Neurosciences, Amsterdam, Netherlands, 3VU University Medical Center, Neurology, Amsterdam," exact="Netherlands" post="Background: Motor dysfunction is well described in multiple sclerosis"/>
  <result pre="Sclerosis Center, Wayne State University School of Medicine, Detroit, MI," exact="United States," post="2Sastry Foundation Advanced Imaging Laboratory, Wayne State University School"/>
  <result pre="Imaging Laboratory, Wayne State University School of Medicine, Detroit, MI," exact="United States," post="3Wayne State University School of Medicine, Department of Diagnostic"/>
  <result pre="University School of Medicine, Department of Diagnostic Radiology, Detroit, MI," exact="United States," post="4Teva Pharmaceutical Industries, Netanya, Israel, 5Teva Pharmaceutical Industries, Cleveland,"/>
  <result pre="4Teva Pharmaceutical Industries, Netanya, Israel, 5Teva Pharmaceutical Industries, Cleveland, OH," exact="United States" post="Background: Identifying MRI outcomes that correlate with disability remains"/>
  <result pre="Psychology, Division of Neuropsychology, Zurich, Switzerland, 4Medizinisch Radiologisches Institut, Zurich," exact="Switzerland" post="Background: Inflammatory lesions and brain atrophy in multiple sclerosis"/>
  <result pre="2Vall Hebron University Hospital, Magnetic Resonance Unit, Neuroradiology Department, Barcelona," exact="Spain" post="Background: Global and regional GM loss occurs only during"/>
  <result pre="1 1NINDS, NIH, Translational Neuroradiology Unit, Neuroimmunology Branch, Bethesda, MD," exact="United States" post="Background: The pathological characteristics of chronic multiple sclerosis (MS)"/>
  <result pre="Lucchinetti 1, I Pirko 1 1Mayo Clinic, Neurology, Rochester, MN," exact="United States," post="2Mayo Clinic, Biomedical Statistics and Informatics, Rochester, MN, United"/>
  <result pre="United States, 2Mayo Clinic, Biomedical Statistics and Informatics, Rochester, MN," exact="United States," post="3Mayo Clinic, Radiology, Rochester, MN, United States, 4Mayo Clinic,"/>
  <result pre="Informatics, Rochester, MN, United States, 3Mayo Clinic, Radiology, Rochester, MN," exact="United States," post="4Mayo Clinic, Biomedical Engineering and Medical Physics, Rochester, MN,"/>
  <result pre="States, 4Mayo Clinic, Biomedical Engineering and Medical Physics, Rochester, MN," exact="United States" post="Background: The relationship between cortical lesions (CL) and white"/>
  <result pre="Center, Radiology, Amsterdam, Netherlands, 3VU University Medical Center, Pathology, Amsterdam," exact="Netherlands" post="Background: Multiple sclerosis (MS) is mostly characterized by its"/>
  <result pre="Technology, Stockholm, Sweden, 2Karolinska Institutet, Department of Clinical Neuroscience, Stockholm," exact="Sweden" post="Background: Cognitive impairment is common in MS and may"/>
  <result pre="Rome, Italy, 2Santa Lucia Fundation, Rome, Italy, 3FMRIB Centre, Oxford," exact="United Kingdom" post="Background: Functional and structural MRI have been widely applied"/>
  <result pre="Italy, 3University of Salerno, Department of Medicine and Surgery, Salerno," exact="Italy" post="Background: Resting-state networks (RSNs) explored by functional MRI (fMRI)"/>
  <result pre="Evangelou 1 1University of Nottingham, Division of Clinical Neuroscience, Nottingham," exact="United Kingdom," post="2Nottingham University Hospitals NHS Trust, Department of Medical Physics,"/>
  <result pre="2Nottingham University Hospitals NHS Trust, Department of Medical Physics, Nottingham," exact="United Kingdom," post="3University of Nottingham, Division of Radiological and Imaging Sciences,"/>
  <result pre="3University of Nottingham, Division of Radiological and Imaging Sciences, Nottingham," exact="United Kingdom," post="4University of Nottingham, Sir Peter Mansfield Magnetic Resonance Centre,"/>
  <result pre="4University of Nottingham, Sir Peter Mansfield Magnetic Resonance Centre, Nottingham," exact="United Kingdom" post="Background: The value of detecting intralesional white matter (WM)"/>
  <result pre="1,2 1University of Oxford, Nuffield Department of Clinical Neurosciences, Oxford," exact="United Kingdom," post="2Oxford University Hospitals NHS Trust, Department of Neurology, Oxford,"/>
  <result pre="Kingdom, 2Oxford University Hospitals NHS Trust, Department of Neurology, Oxford," exact="United Kingdom," post="3University of British Columbia, Vancouver, BC, Canada, 4University of"/>
  <result pre="Canada, 4University of Bristol, Clinical Research and Imaging Centre, Bristol," exact="United Kingdom" post="Background: Inflammatory demyelinating central nervous system lesions are a"/>
  <result pre="Austria, 2Radboud University Nijmegen, Nijmegen, Netherlands, 3University of Oxford, Oxford," exact="United Kingdom" post="Background: The implementation of resting state fMRI (RS-fMRI) in"/>
  <result pre="Scientific Institute, Vita-Salute San Raffaele University, Department of Neuroradiology, Milan," exact="Italy" post="Background: Encoding difficulties are among the causes of memory"/>
  <result pre="2VU University Medical Center, Amsterdam, Netherlands, 3Antwerp University Hospital, Antwerp," exact="Belgium" post="Background: Magnetic Resonance Imaging (MRI) of the brain has"/>
  <result pre="1National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD," exact="United States," post="2University of British Columbia, Statistics, Vancouver, BC, Canada, 3University"/>
  <result pre="Neurology and Radiology, Florence, Italy, 4Myelin Repair Foundation, Saratoga, CA," exact="United States" post="Background: New lesion activity on MRI is used to"/>
  <result pre="Sclerosis Center, Wayne State University School of Medicine, Detroit, MI," exact="United States," post="2Sastry Foundation Advanced Imaging Laboratory, Wayne State University School"/>
  <result pre="Imaging Laboratory, Wayne State University School of Medicine, Detroit, MI," exact="United States," post="3University of New Mexico Health Sciences Center, Albuquerque, NM,"/>
  <result pre="School of Medicine, Detroit, MI, United States, 3University of New" exact="Mexico" post="Health Sciences Center, Albuquerque, NM, United States, 4Teva Pharmaceutical"/>
  <result pre="States, 3University of New Mexico Health Sciences Center, Albuquerque, NM," exact="United States," post="4Teva Pharmaceutical Industries, Cleveland, OH, United States, 5Teva Pharmaceutical"/>
  <result pre="Center, Albuquerque, NM, United States, 4Teva Pharmaceutical Industries, Cleveland, OH," exact="United States," post="5Teva Pharmaceutical Industries, Netanya, Israel Background: Finding MRI metrics"/>
  <result pre="Pharmaceutical Industries, Cleveland, OH, United States, 5Teva Pharmaceutical Industries, Netanya," exact="Israel" post="Background: Finding MRI metrics and techniques to serve as"/>
 </snippets>
</snippetsTree>
